Vorinostat (SAHA, MK0683)

Catalog No.S1047 Synonyms: SAHA, MK0683, suberoylanilide hydroxamic acid

Molecular Weight(MW): 264.3

Vorinostat (suberoylanilide hydroxamic acid, SAHA) is an HDAC inhibitor with IC50 of ~10 nM in a cell-free assay.

Cited by 112 Publications

Nature, 2017, 551(7679):247-250

PubMed: 29088702 ( click the link to review the publication )

Nat Biotechnol, 2015, 10.1038/nbt.3130

PubMed: 25751058 ( click the link to review the publication )

Nat Med, 2015, 10.1038/nm.3855

PubMed: 25939062 ( click the link to review the publication )

Cell, 2014, 158(5):989-99

PubMed: 25131989 ( click the link to review the publication )

Nature, 2011, 471(7337):235-9

PubMed: 21390130 ( click the link to review the publication )

Nat Biotechnol, 2011, 29(3):255-65

PubMed: 21258344 ( click the link to review the publication )

J Pineal Res, 2019, 66(3):e12556

PubMed: 30648757 ( click the link to review the publication )

Haematologica, 2019, 10.3324/haematol.2018.211110

PubMed: 30846494 ( click the link to review the publication )

Cancer Res, 2019, 79(7):1658-1670

PubMed: 30737231 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(5):900-908

PubMed: 30824609 ( click the link to review the publication )

Acta Pharmacol Sin, 2019, 40(5):677-688

PubMed: 30224636 ( click the link to review the publication )

Exp Ther Med, 2019, 17(6):4547-4553

PubMed: 31186678 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(16):3941-3954

PubMed: 29764852 ( click the link to review the publication )

J Control Release, 2018, 275:117-128

PubMed: 29474960 ( click the link to review the publication )

J Hematol Oncol, 2018, 11(1):32

PubMed: 29486795 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(12):2767-2779

PubMed: 30232145 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(12):3139-3149

PubMed: 27986747 ( click the link to review the publication )

Oncotarget, 2017, 10.18632/oncotarget.15017

PubMed: 28157715 ( click the link to review the publication )

J Hum Genet, 2016, 10.1038/jhg.2016.61

PubMed: 27251006 ( click the link to review the publication )

J Hum Genet, 2016, 10.1038/jhg.2016.61

PubMed: 27251006 ( click the link to review the publication )

EMBO Mol Med, 2015, 10.15252/emmm.201404396

PubMed: 25872941 ( click the link to review the publication )

EMBO Mol Med, 2015, 10.15252/emmm.201404580

PubMed: 25759362 ( click the link to review the publication )

Clin Cancer Res, 2015, 10.1158/1078-0432.CCR-14-2701

PubMed: 25813020 ( click the link to review the publication )

Blood Cancer J, 2015, 5:e312

PubMed: 25978432 ( click the link to review the publication )
Int J Cancer, 2015, 136(11):2717-29

PubMed: ( click the link to review the publication )

Acta Neuropathol Commun, 2015, 3(1):22

PubMed: 25853389 ( click the link to review the publication )

Br J Haematol, 2015, 168(3):371-83

PubMed: ( click the link to review the publication )

Epigenetics, 2015, 10.1080/15592294.2015.1039216

PubMed: 25923331 ( click the link to review the publication )

Biochemical Pharmacology, 2015, 94(2):79-90

PubMed: ( click the link to review the publication )

Biochemical Pharmacology, 2015, 94(2):79-90

PubMed: ( click the link to review the publication )

J Biol Chem, 2015, 290(8):5028-40

PubMed: ( click the link to review the publication )

BMC Cancer, 2015, 15(1):273

PubMed: 25880212 ( click the link to review the publication )

FEBS Lett, 2015, 589(10):1080-8

PubMed: 25816750 ( click the link to review the publication )

J Biotechnol, 2015, 10.1016/j.jbiotec.2015.02.029

PubMed: 25746901 ( click the link to review the publication )

Sci Transl Med, 2014, 6(256):256ra135

PubMed: 25273096 ( click the link to review the publication )

Nat Commun, 2014, 5:3361

PubMed: 24553445 ( click the link to review the publication )

Clin Cancer Res, 2014, 10.1158/1078-0432.CCR-14-0384

PubMed: 25355930 ( click the link to review the publication )

Int J Cancer, 2014, 135(7):1721-32

PubMed: 24615207 ( click the link to review the publication )

Diabetes, 2014, 63(9):2924-34

PubMed: 24722245 ( click the link to review the publication )

Cancer Lett, 2014, 10.1016/j.canlet.2014.10.034

PubMed: ( click the link to review the publication )

Cancer Lett, 2014, 351(1):50-8

PubMed: 24814395 ( click the link to review the publication )

PLoS Pathog, 2014, 10(4):e1004071

PubMed: 24722454 ( click the link to review the publication )

PLoS Pathog, 2014, 10(4):e1004071

PubMed: 24722454 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1134

PubMed: 24651437 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1177

PubMed: 24743732 ( click the link to review the publication )

Mol Cancer Ther, 2014, 13(12):2784-92

PubMed: 25319394 ( click the link to review the publication )

J Mol Biol, 2014, 426(20):3442-53

PubMed: 24657767 ( click the link to review the publication )

Hum Gene Ther, 2014, 25(7):599-608

PubMed: 24568341 ( click the link to review the publication )
J Biol Chem, 2014, 289(14):9918-25

PubMed: 24515107 ( click the link to review the publication )

Cancer Cell Int, 2014, 10.1186/s12935-014-0112-x

PubMed: ( click the link to review the publication )

Mol Cell Biol, 2014, 34(7):1280-9

PubMed: 24469401 ( click the link to review the publication )

Proteomics Clin Appl, 2014, 8(11-12):924-31

PubMed: 25091122 ( click the link to review the publication )

J Alzheimers Dis, 2014, 41(4):1193-205

PubMed: 24844691 ( click the link to review the publication )

Cancer Biol Ther, 2014, 15(5):578-85

PubMed: 24556916 ( click the link to review the publication )

BMC Cancer, 2014, 14(1):373

PubMed: 24886166 ( click the link to review the publication )

FEBS Lett, 2014, 588(9):1571-9

PubMed: 24607544 ( click the link to review the publication )

Mol Med Rep, 2014, 10(5):2729-35

PubMed: 25199623 ( click the link to review the publication )

Head Neck, 2014, 10.1002/hed.23822.

PubMed: 24986420 ( click the link to review the publication )

Cytometry A, 2014, 85(1):78-87

PubMed: 24038859 ( click the link to review the publication )

Curr Pharm Desigh, 2014, 20(11):1874-80

PubMed: 23888956 ( click the link to review the publication )

Pharmacology Research Perspectives, 2014, 10.1002/prp2.43

PubMed: ( click the link to review the publication )

Oncotarget, 2014, 5(15):5965-77

PubMed: 25115389 ( click the link to review the publication )

Blood, 2013, 123(5):706-16

PubMed: 24319254 ( click the link to review the publication )

Nat Struct Mol Biol, 2013, 20(3):317-25

PubMed: 23377543 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2013, 111(3):E364-73

PubMed: 24395801 ( click the link to review the publication )

PLoS Biol, 2013, 12(1):e1001758

PubMed: 24409098 ( click the link to review the publication )

Cell Rep, 2013, 5(6):1679-89

PubMed: 24360956 ( click the link to review the publication )

Int J Cancer, 2013, 132(9):2200-8

PubMed: 23024001 ( click the link to review the publication )

Oncogene, 2013, 33(33):4265-72

PubMed: 24292675 ( click the link to review the publication )

Oncogene, 2013, 32(10):1316-29

PubMed: 22543582 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e733

PubMed: 23868066 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e951

PubMed: 24309938 ( click the link to review the publication )
J Biol Chem, 2013, 288(35):25593-602

PubMed: 23878197 ( click the link to review the publication )

J Biol Chem, 2013, 288(20):14400-7

PubMed: 23539624 ( click the link to review the publication )

Mol Carcinog, 2013, 52(3):218-28

PubMed: 22121107 ( click the link to review the publication )

Genes Brain Behav, 2013, 13(1):69-86

PubMed: 24286462 ( click the link to review the publication )

PLoS One, 2013, 8(1):e53766

PubMed: 23320102 ( click the link to review the publication )

J Thromb Thrombolysis, 2013, 35(2):185-92

PubMed: 23229086 ( click the link to review the publication )

J Exp Med, 2012, 209(1):35-50

PubMed: 22231305 ( click the link to review the publication )

Clin Cancer Res, 2012, 18(14):3822-33

PubMed: 22623731 ( click the link to review the publication )

Clin Cancer Res, 2012, 18(2):408-16

PubMed: 22038994 ( click the link to review the publication )

Cancer Res, 2012, 72(9):2251-61

PubMed: 22422937 ( click the link to review the publication )

Cell Death Differ, 2012, 19(12):2029-39

PubMed: 22858545 ( click the link to review the publication )

Cell Death Differ, 2012, 19(8):1317-27

PubMed: 22322857 ( click the link to review the publication )

Eur J Cancer, 2012, 48(7):1096-107

PubMed: 22154545 ( click the link to review the publication )

Diabetologia, 2012, 55(9):2421-31

PubMed: 22772764 ( click the link to review the publication )

FASEB J, 2012, 26(7):3032-41

PubMed: 22459148 ( click the link to review the publication )

J Neurochem, 2012, 123 Suppl 2:108-15

PubMed: 23050648 ( click the link to review the publication )

J Leukoc Biol, 2012, 91(5):701-9

PubMed: 22028329 ( click the link to review the publication )

J Biol Chem, 2012, 287(43):36609

PubMed: 22952229 ( click the link to review the publication )

Mol Carcinog, 2012, 52(6):459-74

PubMed: 22308110 ( click the link to review the publication )

Invest New Drugs, 2012, 30(2):541-7

PubMed: 21107885 ( click the link to review the publication )

Pharm Res, 2012, 29(7):1960-76

PubMed: 22415140 ( click the link to review the publication )

PLoS One, 2012, 7(9):e44265

PubMed: 22957056 ( click the link to review the publication )

PLoS One, 2012, 7(12):e52335

PubMed: 23272238 ( click the link to review the publication )

PLoS One, 2012, 7(12):e52753

PubMed: 23300762 ( click the link to review the publication )
Chronobiol Int, 2012, 29(8):982-93

PubMed: 22891617 ( click the link to review the publication )

Biochem Biophys Res Co, 2012, 420(2):325-30

PubMed: 22425986 ( click the link to review the publication )

Pediatr Surg Int, 2012, 28(6):579-89

PubMed: 22526548 ( click the link to review the publication )

Protein Expr Purif, 2012, 86(1):45-52

PubMed: 21992606 ( click the link to review the publication )

Brain, 2011, 134(Pt 8):2408-21

PubMed: 21772061 ( click the link to review the publication )

Clin Cancer Res, 2011, 17(9):2819-29

PubMed: 21357681 ( click the link to review the publication )

Clin Cancer Res, 2011, 17(16):5311-21

PubMed: 21724551 ( click the link to review the publication )

Genes Dev, 2011, 25(24):2610-8

PubMed: 22016339 ( click the link to review the publication )

J Neurosci, 2011, 31(11):3990-9

PubMed: 21411642 ( click the link to review the publication )

J Transl Med, 2011, 9:37

PubMed: 21477288 ( click the link to review the publication )

Retrovirology, 2011, 2(3):411-23

PubMed: 21966324 ( click the link to review the publication )

PLoS One, 2011, 6(7):e22739

PubMed: 21818379 ( click the link to review the publication )

BMC Neurosci, 2011, 12:50

PubMed: 21615950 ( click the link to review the publication )

Sci Signal, 2010, 3(146):ra80

PubMed: 21045206 ( click the link to review the publication )

J Pharmacol Exp Ther, 2010, 86(16):8765-72

PubMed: 20739454 ( click the link to review the publication )

Exp Dermatol, 2010, 19(12):1096-102

PubMed: 20629733 ( click the link to review the publication )

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Description

Vorinostat (suberoylanilide hydroxamic acid, SAHA) is an HDAC inhibitor with IC50 of ~10 nM in a cell-free assay.

Targets

HDAC ^[1]
(Cell-free assay)

~10 nM

In vitro

Vorinostat inhibits the activities of HDAC1 and HDAC3 with IC50 of 10 nM and 20 nM, respectively. Vorinostat also results in a marked hyperacetylation of histone H4. ^[1] Vorinostat inhibits the growth of three prostate cancer cell lines LNCaP, PC-3 and TSU-Pr1 at micromolar concentrations (2.5-7.5 μM), and induces dose-dependent cell death in LNCaP cells. ^[2] Vorinostat treatment in MCF-7 cells inhibits cell proliferation at an IC50 of 0.75 μM resulting in the accumulation of cells in the G1 and G2-M phase of the cell cycle. Vorinostat also induces differentiation in the estrogen receptor-negative cell line SKBr-3 and the retinoblastoma-negative cell line MDA-468. ^[3] Vorinostat treatment at 1 μM for 8 hours or more is sufficient to irreversibly induce apoptosis of human multiple myeloma (MM) cells. The gene expression profiles of Vorinostat treated MM cells are not hallmarked by global transcriptional activation, but by coordinated transcriptional changes of specific functional groups of genes such as cytokine-induced proliferative/survival signaling cascades, oncogenes-tumor suppressor genes, regulators of apoptosis, DNA synthesis-repair and cell cycle, and proteasome-ubiquitin function. ^[4]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
A20	MWHLbY5ie2ViQYPzZZk>		MnT5NUBp	M2nFWGROW09?	NH;kcFRidnSrLVjERWMyKGGldHn2bZR6KHerdHigTWM2OCCxZjCwMlEyOiEQvF2=	NV\Pe5JOOTF7NkC0PFk>
Friend leukemic cell	M{DVSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFzPemE2OCEQvF2=	M1nTd\|czKGh?	MU\EUXNQ	NVrpSZh{UUN3ME2wMlk6KM7:TR?=	M3PDVlEzOTB7OUGz
K562	NIj5epdMcW6jc3WgRZN{[Xl?		NWTaNnZLPiCq	NVXVOpE{TE2VTx?=	Mm\BTY5pcWKrdHnvckBw\iCqdX3hckBpcXO2b37lJIRm[WOndInsZZNmKCivaYj0eZJmKG:oIFjERWMyKGGwZDDISGFEOilid3n0bEBKSzVyIH;mJFAvODFizszN	M4rlTFEzPDF7M{iw
HT1080	Mo\JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NGjtPY04OiCq	MmjHSG1UVw>?	M2\nZWlEPTB;Mj60JO69VQ>?	MXqxNlI4ODF5NR?=
H1299	NW[5OpNrU2mwYYPlJGF{e2G7		M176ZVIxKG2rbh?=	MonjSG1UVw>?	NVy3V256UW6qaXLpeI9zgSCjY4Tpeol1gSCjZ3HpcpN1KEiGQVOg[Y57gW2nIIfpeIghUUN3MDDv[kAxNjF7NDFOwG0>	Mn7yNVQ2OjF2MkK=
H1299	Ml\pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NH;0WoI4OiCq	NYHKXYY5TE2VTx?=	Mk\HTWM2OD15LkK0JO69VQ>?	NHfOWYQyPDV{MUSyNi=>
HeLa	MXXLbY5ie2ViQYPzZZk>		NWHnUY1LOzBibXnu		MkTQTY5pcWKrdH;yfUBkd26lZX70doF1cW:wIHHnZYlve3RiaHnzeI9v\SCmZXHj[ZR6dGG\|ZTD3bZRpKEmFNUCgc4YhOC5{ODFOwG0>	NHeyPVAyPTZyM{m0PS=>
LOX-IMVI	Mn7nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NVTKN4o{PDhiaB?=		NGC3b\|JKSzVyPUGuN{DPxE1?	M2LiWlE2PzF3NEew
NCI-H226	M37ubWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NGTiXVI1QCCq		NHG2dVBKSzVyPUKuOkDPxE1?	MUmxOVcyPTR5MB?=
RXF-631L	NVzrVpdMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MlP3OFghcA>?		NHv3ZohKSzVyPUKg{txO	NYHXclQ{OTV5MUW0O\|A>
SNB-78	M2W1Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M1;N[lQ5KGh?		MnvoTWM2OD1zNjFOwG0>	MUGxOVcyPTR5MB?=
St-4	NHfaOnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M{X1RVQ5KGh?		MXTJR\|UxRTVwMjFOwG0>	M1jiUVE2PzF3NEew
ARP1	NHjCU4VHfW6ldHnvckBCe3OjeR?=	NGr1[YMzKM7:TR?=	M4n1R\|YhcA>?		NWTGPWc6UW6mdXP0bY9vKG:oIGCyNXdCTjFiZ3Xu[UBmgHC{ZYPzbY9v	NID4bWMyPDd\|NEiwOi=>
CEM	MWDLbY5ie2ViQYPzZZk>		NVzLVZJJOSCq	M3jLV2ROW09?	NIfiXoJKdmirYnn0bY9vKG:oIFjERWMhf2m2aDDJR\|UxKG:oIECuN\|Mh\|ryP	MWWxOlQzODB4NB?=
HCT15	MnrzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MWC0PEBp		NEW2dFJIUTVyPUCuPFIh\|ryP	MmftNVY4OjN{Mke=
NCI-H23	Mme3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M4noWlQ5KGh?		MVPHTVUxRTBwOUKg{txO	MlnuNVY4OjN{Mke=
GM15850	NGnGfmhMcW6jc3WgRZN{[Xl?	NV7nRoFIOi53IN88US=>	Mn7jPVYhcA>?	MVnEUXNQ	NV7peXg5UW6qaXLpeIlwdiCxZjDISGFEKGG\|c3Xzd4VlKGG\|IHnuZ5Jm[XOnIHnuJIhqe3SxbnWgTFMhdHm\|aX7lJFE1KGGlZYT5cIF1cW:wIH;mJGZZViCpZX7l	NFPFZZcyPjl{MUO2Oy=>
GM15850	NIC5PVBMcW6jc3WgRZN{[Xl?	NWfZbI5jOi53IN88US=>	NX7GeGFuQTZiaB?=	NFnKTGFFVVOR	NIrJPWJKdmirYnn0bY9vKG:oIFjERWMh[XO\|ZYPz[YQh[XNiaX7jdoVie2ViaX6gbIl{fG:wZTDIOEBtgXOrbnWgOUBi[2W2eXzheIlwdiCxZjDGXG4h\2WwZR?=	Ml7XNVY6OjF\|Nke=
GM15850	MXzLbY5ie2ViQYPzZZk>	NVjSXHNIOi53IN88US=>	M{Wx[Fk3KGh?	M3XvT2ROW09?	NFvUPVBKdmirYnn0bY9vKG:oIFjERWMh[XO\|ZYPz[YQh[XNiaX7jdoVie2ViaX6gbIl{fG:wZTDIOEBtgXOrbnWgNVIh[WOndInsZZRqd25ib3[gSnhPKGenbnW=	NH\QNnIyPjl{MUO2Oy=>
GM15850	M33F[mtqdmG\|ZTDBd5NigQ>?	NEfzc2QzNjVizszN	M2\DNFk3KGh?	M3z1VWROW09?	M1zWNmlvcGmkaYTpc44hd2ZiSFTBR{Bie3Onc4Pl[EBieyCrbnPy[YF{\SCrbjDobZN1d26nIFizJIx6e2mwZTC5JIFk\XS7bHH0bY9vKG:oIF\YUkBo\W6n	MVOxOlkzOTN4Nx?=
GM15850	MVnLbY5ie2ViQYPzZZk>	NGXKcIkzNjVizszN	NGTl[ZU6PiCq	NX75TVlETE2VTx?=	MYHJcohq[mm2aX;uJI9nKEiGQVOgZZN{\XO\|ZXSgZZMhcW6lcnXhd4UhcW5iaHnzeI9v\SCKNDDsfZNqdmViODDhZ4V1gWyjdHnvckBw\iCIWF6g[4Vv\Q>?	MU[xOlkzOTN4Nx?=
GM15850	NHfGdJJMcW6jc3WgRZN{[Xl?	NUDQOJRCOi53IN88US=>	M{nrd\|k3KGh?	MYfEUXNQ	MlHkTY5pcWKrdHnvckBw\iCKRFHDJIF{e2W\|c3XkJIF{KGmwY4LlZZNmKGmwIHjpd5RwdmViSESgcJl{cW6nIEG2JIFk\XS7bHH0bY9vKG:oIF\YUkBo\W6n	M3iwXVE3QTJzM{[3
U937	NVXXUYdwTnWwY4Tpc44hSXO\|YYm=	NGTn[FE2KM7:TR?=	MVGyOEBp	MULEUXNQ	MlLWR4VtdCCleXPs[UBienKnc4SgZpkh[WOldX31cIF1cW:wIHH0JHMwTzJxTTDwbIF{\Q>?	M1u3XVE4ODB2N{G4
H661	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MUK0PEBp		MXPJR\|UxRTFizszN	MVqxO\|E2PzByOR?=
U937	NFSyc3pHfW6ldHnvckBCe3OjeR?=	MlPVOUDPxE1?	NHm0fIszPCCq	NEj6fJRFVVOR	MV3JcoNz\WG\|ZTDpckBpcXO2b37lJGg{KGGlZYT5cIF1cW:w	NIPRWZcyPzR2N{e1NC=>
U937	NVn3[pRGTnWwY4Tpc44hSXO\|YYm=	MVqxJO69VQ>?	M1XzSVI1KGh?	NWDxNFlpTE2VTx?=	NEHoT3dG\m[nY4Sgc44h[WyyaHGgeJVjfWyrbjDhZ4V1gWyjdHnvci=>	MX:xO\|Q1Pzd3MB?=
RAW264.7	MUjGeY5kfGmxbjDBd5NigQ>?	M{H2XlExKM7:TR?=	NIrScHQzPGh?	NYrpUJFDf2G2ZYK=	NFTMPWxKdmirYnn0bY9vKG:oIFzQV{1{fGmvdXzheIVlKFSQRnHsdIhiKHC{b3T1Z5Rqd25id3n0bEBKSzVyIH;mJFAvPzZizszN	NGCyO2IyPzR5N{WxPC=>
RAW264.7	M4jLWGZ2dmO2aX;uJGF{e2G7	M4XQXVExKM7:TR?=	NWDYXVN4OjSq	NEjvcXR4[XSnch?=	NUPRZVJ3UW6qaXLpeIlwdiCxZjDMVHMue3SrbYXsZZRm\CCQTzDwdo9lfWO2aX;uJJdqfGhiSVO1NEBw\iBzLki4JO69VQ>?	M{Gy[VE4PDd5NUG4
SC9	NUfMVodOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NUSzUHNRPDhiaB?=		NGLnTY5KSzVyPUCuOlA3KM7:TR?=	MUmxO\|UxPzJzOR?=
ST14A	M1XF[2Z2dmO2aX;uJGF{e2G7	NESySpU2KG6P	M3H1TVczKGh?		MnftTY5kemWjc3WgbY4hWkWVVD;OVnNHKG2UTlGg[ZhxemW\|c3nvci=>	NYL2Zm1iOTd3NkW5PVM>
ST14A	NVHBXoF5TnWwY4Tpc44hSXO\|YYm=	NHjqe5c2KG6P	NGfOVIY4OiCq		MWXJcoNz\WG\|ZTDpckBGOkZzIH3SUmEh\XiycnXzd4lwdg>?	MXSxO\|U3PTl7Mx?=
PANC1	MlHnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkfmNUDPxE1?			NYTldWVDUUN3ME2wMlQ2KM7:TR?=	M{LLcFE4PTh6N{S0
PANC1	NWjkXHdwTnWwY4Tpc44hSXO\|YYm=	NULWNYQ{OSEQvF2=	Mn;rNlQhcA>?		MlvHTY5kemWjc3WgbY4heDJzV1HGNU9EUVBzIHflcoUh\XiycnXzd4lwdg>?	NYjG[FBFOTd3OEi3OFQ>
PANC1	Ml\ISpVv[3Srb36gRZN{[Xl?	MmfTNUDPxE1?	NYDIc5BwOjRiaB?=		MYjJcoNz\WG\|ZTDpckBxOjetaYCxJIdmdmViZYjwdoV{e2mxbh?=	M3nUWFE4PTh6N{S0
PT45	NW[3T3hoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1;nUGlEPTB;NDFOwG0>	NULWW\|ZOOTd3OEi3OFQ>
ACHN	MlW1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M{LKRlIyKGh?		MnjES2k2OD1yLk[1JO69VQ>?	MUOxO\|Y3OjZyNh?=
PC3	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NYfaVWUxOjFiaB?=		M2\nS2dKPTB;MD63NUDPxE1?	NInpTHQyPzZ4Mk[wOi=>
A431	M1T4N2N6fG:2b4jpZ{BCe3OjeR?=		NH2wSFU4OiCq		MULJR\|UxRTRwMjFOwG0>	M3;jNFE4PjlzN{[z
Cal27	MWDDfZRwfG:6aXOgRZN{[Xl?		NYTLeId3PzJiaB?=		M1izcmlEPTB;Mz6yJO69VQ>?	NIPTTnEyPzZ7MUe2Ny=>
CCRF-CEM	M33YUWN6fG:2b4jpZ{BCe3OjeR?=		MYC3NkBp		MnnyTWM2OD1yLkig{txO	M2nvNFE4PjlzN{[z
EOL1	NEK2XJhEgXSxdH;4bYMhSXO\|YYm=		MUK3NkBp		MYTJR\|UxRTFizszN	NVPuXWJmOTd4OUG3OlM>
Hec-1-A	NVnMWnhbS3m2b4TvfIlkKEG\|c3H5		M37PdVczKGh?		NIfLNJVKSzVyPUGg{txO	NVvRWXZFOTd4OUG3OlM>
HeLa	NXrwO5l5U2mwYYPlJGF{e2G7	MX:xNEDPxE1?	MY[zNEBucW5?	MVzEUXNQ	MYjJcohq[mm2aX;uJI9nKHKnY3;tZolv[W62IFjERWMyKHerdHigTWM2OCCxZjCwMlAzKM7:TR?=	MVWxO\|Y6OTd4Mx?=
RKOp21	MXjDfZRwfG:6aXOgRZN{[Xl?		NXz6V\|J3PzJiaB?=		Mlf0TWM2OD1zLke2JO69VQ>?	MlrNNVc3QTF5NkO=
Saos2	MXTDfZRwfG:6aXOgRZN{[Xl?		MUG3NkBp		NHPIXnZKSzVyPUKuN{DPxE1?	MlGwNVc3QTF5NkO=
SK-OV-3	NYrtSJg5S3m2b4TvfIlkKEG\|c3H5		MljYO\|IhcA>?		MX7JR\|UxRTJwMjFOwG0>	NF\1eZYyPzZ7MUe2Ny=>
U87MG	NVHufoxiS3m2b4TvfIlkKEG\|c3H5		MXS3NkBp		M2SyemlEPTB;MUGg{txO	MmXHNVc3QTF5NkO=
NUGC3	NVXhdIpQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{[zUVUh\|ryP	M2f6VlI1KGh?		NIPaclJIUTVyPUKuO\|kh\|ryP	Mnm4NVc6ODR6NEO=
CCD1059SK	MlTyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFz4VJhKSzVyPUSzMlUh\|ryP	Mli2NVgzPDd3NUS=
HepG2	NX7XeJdtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGXkSG1KSzVyPUCuNFAxPiEQvF2=	NIrTcnAyQDJ2N{W1OC=>
HT1080	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHPTcJBKSzVyPUCuNFAzPCEQvF2=	NFi4[5kyQDJ2N{W1OC=>
SKBR3	Ml7TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIDNOJhKSzVyPUCuPEDPxE1?	MWexPFI1PzV3NB?=
SNB78	Mly5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mny2SWM2OD1zNjFOwG0>	NYPMTFJFOTh{NEe1OVQ>
SQ20B	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MULJR\|UxRTNizszN	NF7ObVEyQDJ2N{W1OC=>
St4	NFnFbZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUfEfnNDTUN3ME21MlIh\|ryP	MoT6NVgzPDd3NUS=
MCF7	MYPGeY5kfGmxbjDBd5NigQ>?	NWHwSY5XOTBizszN	M2CzPVghcA>?	MWfEUXNQ	Ml;qTY5lfWO2aX;uJI9nKHS3YoXsbY4hcHmyZYLhZ4V1gWyjdHnvci=>	NF32dZcyQDJ4OUKyOi=>
HEK293	NWf3clBXU2mwYYPlJGF{e2G7		MVWxJIg>	NH;rT3pFVVOR	M2frPGlvcGmkaYTpc44hd2ZiSFTBR\|Ehf2m2aDDJR\|UxKG:oIECuNFMh\|ryP	M4nrWFE5OzB6NU[z
HEK293	NWHYbmdOU2mwYYPlJGF{e2G7		NXLtPZh2OSCq	Ml;TSG1UVw>?	MnO1TY5pcWKrdHnvckBw\iCKRFHDN{B4cXSqIFnDOVAhd2ZiMD6wOVch\|ryP	NEHYTYsyQDNyOEW2Ny=>
G401	Mo\nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NGXrfXY4OiCq	NIXZOWpFVVOR	NX7CUJlDUUN3ME2xJO69VQ>?	NG\2flIyQDN5MEO3Ny=>
HeLa	NXfGZ2VMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M1qxZVczKGh?	NW\tZYd4TE2VTx?=	M1zKPGlEPTB;MD60OkDPxE1?	NHTzdWoyQDN5MEO3Ny=>
Human renal epithelial cell	NVr4R2F{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MX:3NkBp	NYnvRXh4TE2VTx?=	MX;JR\|UxRTF2IN88US=>	M1GzUFE5OzdyM{ez
U937	M2nCS2Z2dmO2aX;uJGF{e2G7	MV[1JO69VQ>?	NUn2dpc5OjRiaB?=		MlTmTY5lfWO2aX;uJI9nKGirc4TvcoUhUDRiaInw[ZJi[2W2eXzheIlwdg>?	MWixPFM5OTJ\|OB?=
U937	MYXGeY5kfGmxbjDBd5NigQ>?	NXXieohbPSEQvF2=	NGmwc\|czPCCq		NYPEc21RUW6mdXP0bY9vKG:oIHHsdIhiKHS3YoXsbY4hcHmyZYLhZ4V1gWyjdHnvci=>	NFH6W3cyQDN6MUKzPC=>
U937	M1m3[WZ2dmO2aX;uJGF{e2G7	MmqwOUDPxE1?	MXKyOEBp		MX3JcoR2[3Srb36gc4YheDJzIHX4dJJme3Orb36=	Mmr1NVg{QDF{M{i=
U937	M4\HSWZ2dmO2aX;uJGF{e2G7	M1:y[\|Uh\|ryP	M2DGcFI1KGh?		M37lWmlv\HWldHnvckBw\iCjcH;weI9{cXN?	NFft[nIyQDN6MUKzPC=>
U937	NV[3WnU{TnWwY4Tpc44hSXO\|YYm=	NHn6fHI2KM7:TR?=	NGjsVlgzPCCq		NGHldlVKdmS3Y4Tpc44hd2ZiZ4LhcpVtd2O7dHnjJIRq\m[ncnXueIlifGmxbh?=	MYqxPFM5OTJ\|OB?=
U937	NUDOfG44U2mwYYPlJGF{e2G7	MmTnOUDPxE1?	MoDCNlQhcA>?		MXXJcohq[mm2aX;uJI9nKGi3bXHuJGhFSUNz	MYGxPFM5OTJ\|OB?=
U937	MWnLbY5ie2ViQYPzZZk>	M2rEd\|Uh\|ryP	NXfDXIFyOjRiaB?=		M{PDc2lvcGmkaYTpc44hd2ZiaIXtZY4hUESDQ{S=	M3fCblE5OzhzMkO4
HEK-TE	NXS1SpVRTnWwY4Tpc44hSXO\|YYm=	NWPQWpB{PSEQvF2=	NHLJSpM3cA>?	NXvFUFNzTE2VTx?=	NGrBbJNKdmO{ZXHz[UBqdiCqaYP0c45mKEh\|IHHj[ZR6dGG2aX;u	NH7BRmcyQDR\|NEG0OC=>
HPDE6c7	MXvDfZRwfG:6aXOgRZN{[Xl?	NWr5PYp5PTBizszN	M3jteFczKGh?	MlvMSG1UVw>?	MknhTWM2OD1zLkOg{txO	MnLBNVg1QTR2NkO=
Human microvascular epithelial cell	NIPLcGxEgXSxdH;4bYMhSXO\|YYm=	Mn3TOVAh\|ryP	M2ex[VczKGh?	MlTkSG1UVw>?	NWDaUYs2UUN3ME2xMlMh\|ryP	NGjFXo4yQDR7NES2Ny=>
Hup T3	NFrBOYlEgXSxdH;4bYMhSXO\|YYm=	MnPGOVAh\|ryP	MlvWO\|Jp	MkXsSG1UVw>?	NXe4NJg2UUN3ME2wMlgh\|ryP	NIfxbmIyQDR7NES2Ny=>
Mia Paca2	NF;yfnFEgXSxdH;4bYMhSXO\|YYm=	NUfZfJp4PTBizszN	NXXL[Yh4PzKq	MWfEUXNQ	MXfJR\|UxRTFwMTFOwG0>	NEnMW2cyQDR7NES2Ny=>
Panc 04.03	NWHyclVPS3m2b4TvfIlkKEG\|c3H5	Mmi4OVAh\|ryP	NUDjS45UPzKq	NXfOWncyTE2VTx?=	M{n5dWlEPTB;MT6yJO69VQ>?	Mkf4NVg1QTR2NkO=
SU 86.86	NETkRVdEgXSxdH;4bYMhSXO\|YYm=	Mmr2OVAh\|ryP	Mke3O\|Jp	NFy2VGRFVVOR	MXPJR\|UxRTFwMzFOwG0>	MXmxPFQ6PDR4Mx?=
HEK293	M37TOmtqdmG\|ZTDBd5NigQ>?		M4GwU\|MhcA>?		MYHJcohq[mm2aX;uJI9nKHKnY3;tZolv[W62IFjERWM3KGW6cILld5Nqd25id3n0bEBKSzVyIH;mJFAvODF7IN88US=>	MnzGNVg2PTh4Nkm=
HeLa	NEnCTWZMcW6jc3WgRZN{[Xl?		NV\lVI9zOiCq		MYTJcohq[mm2aX;uJI9nKG63Y3zlZZIhUESDQzD3bZRpKEmFNUCgc4YhOC5yOEOg{txO	MUexPFU2QDZ4OR?=
RAW264.7	NHX1RWRHfW6ldHnvckBCe3OjeR?=	NIL5[FIzKM7:TR?=	M3XmO\|MvPSCq	NGH1ZopFVVOR	MnnLRY51cW2jbHHybYFtKGGldHn2bZR6KGGpYXnud5QhWGyjc33v[Il2dSCoYXzjbZBienWvIHnu[oVkfGWmIIfpeIghUUN3MDDv[kAxNjFzIN88US=>	MmqwNVg3PDR7Nkm=
NB4			M33NTlQ5cA>?	NFzMN3BFVVOR	M3LONWlEPTB;MD62JO69VQ>?	NV;Ke4JsOTh5MkOzOFk>
HEK293	NH\6NpNHfW6ldHnvckBCe3OjeR?=	NY\o[mVQOTBizszN	MX6yOEBp	MnjHSG1UVw>?	MXfBZ5RqfmG2aX;uJI9nKG2xdYPlJHdvfDOjIIPp[45idGmwZzDlfJBz\XO\|ZXS=	M2eyfFE6ODJ{Nke1
HCT116	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MlfwO\|Jp	M3zY[mROW09?	MXXJR\|UxRTBwM{Gg{txO	NUn6blRjOTlyOESyPVQ>
HeLa	NFLo[lFMcW6jc3WgRZN{[Xl?	MVOyJO69VQ>?	NX\XbFRrOzBibXnu	M2PsbmROW09?	MUDJcohq[mm2aX;uJI9nKEiGQVOyJIlvKGi3bXHuJGhmVGFiY3XscJMhf2m2aDDJR\|UxKG:oIECuNUDPxE1?	MXKxPVA5PDJ7NB?=
IGROV1	NVXicmZZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MVe3NkBp	NGPTRW5FVVOR	M3GyPWlEPTB;Mj6yJO69VQ>?	MoP5NVkxQDR{OUS=
IGROV1	M2Hvd2tqdmG\|ZTDBd5NigQ>?	NEi2[4I2KM7:TR?=	NWTu[\|J{OjRiaB?=	MXvEUXNQ	MVHJcohq[mm2aX;uJI9nKEiGQVOgZZN{\XO\|ZXSgZZMheDV\|IHHj[ZR6dGG2aX;u	NXXDSZVXOTlyOESyPVQ>
IGROV1	M3vmbGtqdmG\|ZTDBd5NigQ>?	NWHwTXJlOTBizszN	M1jYUFQhcA>?	NVHGSYtJTE2VTx?=	NGDScFJKdmirYnn0bY9vKG:oIFjERWMh[XO\|ZYPz[YQh[XNiaHnzeI9v\S2KNDDhZ4V1gWyjdHnvci=>	NIHDUoIyQTB6NEK5OC=>
IGROV1	M4e0O2tqdmG\|ZTDBd5NigQ>?	NY[yRXR1OTBizszN	NEDDOY01KGh?	MYrEUXNQ	MlrLTY5pcWKrdHnvckBw\iCKRFHDOkBie3Onc4Pl[EBieyCjbIDoZU11fWK3bHnuJIFk\XS7bHH0bY9v	MkK1NVkxQDR{OUS=
T24	MV;LbY5ie2ViQYPzZZk>		M13MRVMhcA>?		MWLJcoR2[3Srb36gc4YhcGm\|dH;u[UBJOyCjY3X0fYxifGmxbjD3bZRpKEWFNUCgc4YhOC5zMjFOwG0>	MV2xPVA5PDN7NR?=
T24	MlKxT4lv[XOnIFHzd4F6		MXWzJIg>		MYPJcoR2[3Srb36gc4Yh[WyyaHGgeJVjfWyrbjDhZ4V1gWyjdHnvckB4cXSqIFXDOVAhd2ZiMD6yOUDPxE1?	Mnj1NVkxQDR\|OUW=
HeLa	M1HPSWtqdmG\|ZTDBd5NigQ>?		MnjjNVUhdWmw	MmHtSG1UVw>?	MmT1TY5pcWKrdHnvckBw\iCKRFHDOkBnem:vIH71Z4xm[XJiZYj0doFkfCC5aYToJGlEPTBib3[gNE4xQDV3IN88US=>	MnTGNVkxQTN6OES=
HeLa	NUfpV\|R6U2mwYYPlJGF{e2G7		MYixOUBucW5?	NFXxSYxFVVOR	Mom3TY5pcWKrdHnvckBw\iCKRFHDPEBnem:vIH71Z4xm[XJiZYj0doFkfCC5aYToJGlEPTBib3[gNU45PiEQvF2=	MmXDNVkxQTN6OES=
NCI-H69	MWDDfZRwfG:6aXOgRZN{[Xl?		MYG3NkBp	MlnoSG1UVw>?	MmTkTWM2OD1{LkC2JO69VQ>?	MkHhNVkxQTN6OES=
SKMES1	MmT0R5l1d3SxeHnjJGF{e2G7		NFTLSXQ4OiCq	MXfEUXNQ	M4DiS2lEPTB;Mj60NkDPxE1?	NWLVUXFMOTlyOUO4PFQ>
S2	MoD1T4lv[XOnIFHzd4F6	NEftUGYxNjFvMUCg{txO	NUDUOXpzOSCq		MXHJcohq[mm2aX;uJI9nKFCuYYPtc4RqfW1iZnHsZ4lx[XK3bTDISGFEOSCneIDy[ZN{\WRid3n0bEBKSzVyIH;mJFAvODV7IN88US=>	NEi4cY8yQTNzN{S1NC=>
SHSY5Y	Mlq2T4lv[XOnIFHzd4F6	NUiweGR3OTBizszN	NEjiVYY1QCCq	MWfEUXNQ	M37xR2lvcGmkaYTpc44hd2ZiSFTBR{B4cXSqIFnDOVAhd2ZiMD61JO69VQ>?	NVrpWoFPOTl\|NESxO\|U>
SHSY5Y	M3POSWN6fG:2b4jpZ{BCe3OjeR?=	M4Phb\|ExKM7:TR?=	MljjOFghcA>?	NHXJW3ZFVVOR	NVPLUXFLUUN3ME2yJO69VQ>?	MWCxPVM1PDF5NR?=
DMS114	NGjTVVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NXPOSpl7PDhiaB?=		NFnyWmhIUTVyPUKuPUDPxE1?	M{\zflE6PDF7MkC1
HBC5	M2njWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NEXISFM1QCCq		NV;rc45uT0l3ME2xO{DPxE1?	MYqxPVQyQTJyNR?=
SNB78	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MWG0PEBp		M3LSU2dKPTB;MU[g{txO	M2jyPVE6PDF7MkC1
HeLa	NIXp[oNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NIKxVHc4OiCq	Mn\HSG1UVw>?	MkjQTWM2OD1yLkS2JO69VQ>?	Mn7aNVk1PDF6NE[=
BHK	NX3zSIlzU2mwYYPlJGF{e2G7	NF7OOo02KM7:TR?=	NVXTXo9COjRiaB?=	MYPEUXNQ	NH3MOYJKdmirYnn0bY9vKG:oIFjERWM4KGW6cILld5Nm\CCjc4Pld5Nm\CCjczDpcoNz\WG\|ZTDpckBxdGG\|bXGgcYVu[nKjbnWgSoRmdHSjNUC4JGNHXFJicILveIVqdg>?	NVXIT4tCOTl7Nk[3PFk>
CFBE41o-	NVvCfVd5U2mwYYPlJGF{e2G7	NIHZ[I42KM7:TR?=	M2DoTVghcA>?	NUfu[WkxTE2VTx?=	MWrJcohq[mm2aX;uJI9nKEiGQVOgZZN{\XO\|ZXSgZZMhcHmyZYLhZ4V1gWyjdHnvckBw\iCqaYP0c45mKEh\|	MVyxPVk3Pjd6OR?=
CFBE41o-	M1;a[WtqdmG\|ZTDBd5NigQ>?	NUDaUVhvPSEQvF2=	M4PIRVQhcA>?	NG\RdJdFVVOR	MmXvTY5pcWKrdHnvckBw\iCKRFHDJIF{e2W\|c3XkJIF{KGmwY4LlZZNmKGmwIH31eIFvfCCIZHXseIE2ODhiQ1\UVkBxem:2ZXnuJIxmfmWu	NF:3WlUyQTl4Nke4PS=>
CFBE41o-	M2G5fWtqdmG\|ZTDBd5NigQ>?	M4GwR\|Eh\|ryP	MWWxJIg>	MXfEUXNQ	Mn;1TY5pcWKrdHnvckBw\iCKRFHDJIF{e2W\|c3XkJIF{KGmwY4LlZZNmKGmwIFPGWHIheHKxdHXpckBt\X[nbB?=	MWixPVk3Pjd6OR?=
Primary bronchial epithelial cell	NWPZZpNqU2mwYYPlJGF{e2G7	MXmxJO69VQ>?	NHfBZY0zPCCq	NX3FfGhRTE2VTx?=	NE\6dJJKdmirYnn0bY9vKG:oIFjERWM4KGG\|c3Xzd4VlKGG\|IHnu[JVkfGmxbjDv[kBufXSjboSgSoRmdHSjNUC4JGNHXFJicILveIVqdiCjcHnjZYwhe3W{ZnHj[UBtd2OjbHn6ZZRqd25?	M2PCVlE6QTZ4N{i5
CFBE41o-	M2nzfmtqdmG\|ZTDBd5NigQ>?	NGrXdWUyKM7:TR?=	Mk\ZOUBl[Xm\|	NUD5UWpDTE2VTx?=	NVrQNI5yUW6qaXLpeIlwdiCxZjDISGFEPyCjc4Pld5Nm\CCjczDpcoNz\WG\|ZTDpckB{fGGkaXzpfoF1cW:wIH;mJGZl\Wy2YUWwPEBETlSUIIDyc5RmcW5?	NIm1RpgyQTl4Nke4PS=>
CFBE41o-	NG\KPWlMcW6jc3WgRZN{[Xl?	MVuxJO69VQ>?	NUTj[ZZmOjRiaB?=	MWTEUXNQ	MV7Jcohq[mm2aX;uJI9nKEiGQVO3JIF{e2W\|c3XkJIF{KGmwY4LlZZNmKGmwIF\k[Yx1[TVyODDDSnRTKHC{b4TlbY4hfHKjZn\pZ4tqdmd?	MYixPVk3Pjd6OR?=
CFBE41o-	NIfGOY1McW6jc3WgRZN{[Xl?	NXvSPGZqPSEQvF2=	NEPOZVIzPCCq	NXu3eW1OTE2VTx?=	NYHsOnVRUW6qaXLpeIlwdiCxZjDISGFEPyCjc4Pld5Nm\CCjczDpcoNz\WG\|ZTDpckBz[XSnIH;mJI1ifHW{YYTpc44hd2ZiQ1\UVkBxem:2ZXnuJJRwKGm2czDncJlkd2[xcn2=	NVK0TYxsOTl7Nk[3PFk>
CFBE41o-	MorHT4lv[XOnIFHzd4F6	NFi1b442KM7:TR?=	MVmyOEBp	MkLxSG1UVw>?	M4LtVGlvcGmkaYTpc44hd2ZiSFTBR\|ch[XO\|ZYPz[YQh[XNiaX7jdoVie2ViaX6gd5Ri[mmuaYT5JI9nKE[mZXz0ZVUxQCCFRmTSJJBzd3SnaX6=	NFW5SIIyQTl4Nke4PS=>
CFBE41o-	M1jyXGtqdmG\|ZTDBd5NigQ>?	NF3VRpY2KM7:TR?=	M4L6NVI1KGh?	MWfEUXNQ	MXXJcohq[mm2aX;uJI9nKEiGQVO3JIF{e2W\|c3XkJIF{KGOxcoLlZ5Rqd25ib3[gcZV1[W62IF\k[Yx1[TVyODDDSnRTKHS{YX\mbYNscW6pIITvJINmdGxic4Xy[oFk\SCjczDncJlkd2[xcn2=	MVGxPVk3Pjd6OR?=
Primary bronchial epithelial cell	NWTafFNFU2mwYYPlJGF{e2G7	MoHJOUDPxE1?	MVuyOEBp	M3GwPGROW09?	NIG3fVVKdmirYnn0bY9vKG:oIFjERWMh[XO\|ZYPz[YQh[XNiaX7keYN1cW:wIH;mJI12fGGwdDDG[IVtfGF3MEigR2ZVWiCycn;0[YlvKGGyaXPhcEB{fXKoYXPlJIxw[2GuaYrheIlwdg>?	NUTzR4xtOTl7Nk[3PFk>
Primary bronchial epithelial cell	MVvLbY5ie2ViQYPzZZk>	MXWxJO69VQ>?	MUK5OkBp	MoD3SG1UVw>?	NX3ae\|AzUW6qaXLpeIlwdiCxZjDISGFEPyCjc4Pld5Nm\CCjczDpcoNz\WG\|ZTDpckB{cG:{dDDjbZJkfWm2IHP1dpJmdnS\|	M4\lSVE6QTZ4N{i5
BxPC3	NGXhSYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NV\EUIpZPzJiaB?=		Mnu2TWM2OD1{Lkeg{txO	NH\P[GszODF2M{e3PC=>
CAL27	NX;Yd4RRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NWXkNm1DPzJiaB?=		MX3JR\|UxRTNwN{Kg{txO	M{i3XlIxOTR\|N{e4
Capan1	MlvrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MUG3NkBp		NF7GbmtKSzVyPUeuN{DPxE1?	MVmyNFE1Ozd5OB?=
HCC827	NUjhN\|dXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NELlO4w4OiCq		Mn\mTWM2OD1zLkig{txO	MkXvNlAyPDN5N{i=
LNCAP	NFq3Z4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NYWxcYlyPzJiaB?=		MnW5TWM2OD1yLkW4JO69VQ>?	M4PWOVIxOTR\|N{e4
NCI-H2122	NFLJbWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M3jYUVczKGh?		MoTYTWM2OD15LkWg{txO	NF\XXpAzODF2M{e3PC=>
NCI-H358	NETRNGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NEPibIE4OiCq		MV7JR\|UxRTJwNTFOwG0>	NH7nSWgzODF2M{e3PC=>
SCC15	MnP0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MnHGO\|IhcA>?		MVrJR\|UxRTJwNEmg{txO	M3vQWVIxOTR\|N{e4
SCC25	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M2nyPFczKGh?		M1HHVWlEPTB;MT65N{DPxE1?	Mo\WNlAyPDN5N{i=
SKHEP1	NXS0So9RT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MVS3NkBp		NUS2W5BHUUN3ME2zMlQ3KM7:TR?=	MkOyNlAyPDN5N{i=
BJ	NVThfJpYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3XneFExOCEQvF2=	Mn3WOFghcA>?	MkGxSG1UVw>?	MV7Hdo94fGhiaX7obYJqfGmxbjDheEAxNjB3IITvJFExOCC3TR?=	NFfXTZUzODF2M{i0NC=>
MUF	M1j6TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVqxNFAh\|ryP	Mk\2OFghcA>?	MX;EUXNQ	MXfHdo94fGhiaX7obYJqfGmxbjDheEAxNjB3IITvJFExOCC3TR?=	MlrUNlAyPDN6NEC=
Caco-2	NEK5VpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnjXNVAxKM7:TR?=	MoX5OFhp	MojsSG1UVw>?	MlXQTWM2OD16LkGg{txO	MYGyNFE1Ozh2MB?=
Caco-2	NVK4VZk2U2mwYYPlJGF{e2G7	NF\BfZk2KM7:TR?=	M3LVN\|QhcA>?	MVfEUXNQ	NUj4d2M{UW6mdXP0bY9vKG:oIFjERWMudWWmaXH0[YQhcGm\|dH;u[UBi[2W2eXzheIlwdiCLQ{WwJI9nKDBwMEO3JO69VQ>?	MXiyNFE1Ozh2MB?=
Caco-2	Mm\WT4lv[XOnIFHzd4F6	M{G4ZVAvOzF4IH7NJJRwKDNzLk[g{txO	M3;LVlQhcA>?	MlXDSG1UVw>?	NGjDZ\|BGgCC4aY\vJIlvcGmkaYTpc44hd2ZiaIXtZY4hUESDQ{Gge4l1cCCLQ{WwJI9nKDBwMUG5JO69VQ>?	NInkNIkzODF2M{i0NC=>
Caco-2	NXvEc\|B6U2mwYYPlJGF{e2G7	MXSwMlMyPiCwTTD0c{A{OS54IN88US=>	NUXBS4JOPCCq	NV3YS5ozTE2VTx?=	NVSwNI5RTXhidnn2c{BqdmirYnn0bY9vKG:oIHj1cYFvKEiGQVOzJJdqfGhiSVO1NEBw\iByLkG0O{DPxE1?	MYCyNFE1Ozh2MB?=
Caco-2	MoSwT4lv[XOnIFHzd4F6	MUO2MlMzKG6PIITvJFY{OiEQvF2=	NVvnTmtKPCCq	M3PObmROW09?	MYTFfEB3cX[xIHnubIljcXSrb36gc4YhcHWvYX6gTGRCSzVid3n0bEBKSzVyIH;mJFEzNjZizszN	MnjLNlAyPDN6NEC=
Caco-2	MUfLbY5ie2ViQYPzZZk>	NFvRUIs3NjN{IH7NJJRwKDZ\|MjFOwG0>	NGCzeHU1KGh?	NF;NflJFVVOR	NWj1dXBsTXhidnn2c{BqdmirYnn0bY9vKG:oIHj1cYFvKEiGQVO3JJdqfGhiSVO1NEBw\iB2MTFOwG0>	MmTjNlAyPDN6NEC=
Caco-2	MnjkT4lv[XOnIFHzd4F6	M3PleVAvOzF4IH7NJJRwKDNzLk[g{txO	MkK1OEBp	M4LWW2ROW09?	M{j6WmV5KH[rdn:gbY5pcWKrdHnvckBw\iCqdX3hckBJTEGFNh?=	M3GxSVIxOTR\|OESw
HepG2	NHXadXZMcW6jc3WgRZN{[Xl?	M1jYPVUh\|ryP	MmTnOog>	M1XhUGROW09?	MWfJcoR2[3Srb36gc4YhUESDQz3t[YRq[XSnZDDobZN1d26nIHHj[ZR6dGG2aX;u	NXfMbGt[OjBzNEO4OFA>
HepG2	MUTLbY5ie2ViQYPzZZk>	MVK1JO69VQ>?	NVfIWYExPmh?	NYrnfo5nTE2VTx?=	MkTQTY5lfWO2aX;uJI9nKEiGQVOtcYVlcWG2ZXSgbIl{fG:wZTDofZBmemGlZYT5cIF1cW:w	MkL1NlAyPDN6NEC=
HepG2	Mk[2T4lv[XOnIFHzd4F6	NWDte5dvPSEQvF2=	NGTRc\|A3cA>?	M4\BU2ROW09?	MYPJcoR2[3Srb36gc4YhUESDQz3t[YRq[XSnZDDhcJBp[S22dXL1cIlvKGGlZYT5cIF1cW:w	MYWyNFE1Ozh2MB?=
HepG2	M2fwVWtqdmG\|ZTDBd5NigQ>?	MUi1JO69VQ>?	NF2zUYc3cA>?	MmXLSG1UVw>?	MV7JcoR2[3Srb36gc4YhUESDQz3t[YRq[XSnZDDIN{9JPCCqaYP0c45mKGGlZYT5cIF1cW:w	NFn5[5czODF2M{i0NC=>
COLO205	NX\iVWtxU2mwYYPlJGF{e2G7	MXOxNEDPxE1?	NHfnUHczPCCq	M2jsb2ROW09?	M3;0WmlvcGmkaYTpc44hd2ZiSFTBR\|Eh[XO\|ZYPz[YQh[XNiaX7keYN1cW:wIH;mJIhqe3SxbnWgTFMh[WOndInsZZRqd25id3n0bEBKSzVyIH;mJFIvOiEQvF2=	MY[yNFQ2OTN5OB?=
SCC4	MV3LbY5ie2ViQYPzZZk>	NVyxcldyOSEQvF2=	NVflWFBvOjSq		MVPJcohq[mm2aX;uJI9nKEiGQVOgZZN{\XO\|ZXSgZZMhcW6lcnXhd4UhcW5idIXieYxqdiCjY3X0fYxifGmxbh?=	MmTSNlA1PTJ{MkW=
SCC4	MlfYT4lv[XOnIFHzd4F6	NF7keGcyKM7:TR?=	NX\oc4YxOjSq		NIqwcohKdmirYnn0bY9vKG:oIFjERWMh[XO\|ZYPz[YQh[XNiaX7jdoVie2ViaX6gbIl{fG:wZTDhZ4V1gWyjdHnvci=>	NXvtWWJCOjB2NUKyNlU>
SCC4	NFvvZndHfW6ldHnvckBCe3OjeR?=	M3jQWlEh\|ryP	MWW1JI1qdg>?		M2fJOmFod26rc4SgZYN1cX[rdImgZZQhXkSUIHHzd4V{e2WmIHHzJIlv\HWldHnvckBw\iCFWWCyOEBo\W6nIHX4dJJme3Orb36=	MnvoNlA1PTJ{MkW=
NB4	MUDGeY5kfGmxbjDBd5NigQ>?	MWS1JO69VQ>?	MYiyOEBp	NWfuNpV7TE2VTx?=	NVTydXU3S2WubDDjfYNt\SCjcoLld5Qh[XO\|ZYPz[YQh[XNiaX7jdoVie2ViaX6gZYNkfW23bHH0bY9vKGG2IIDy[U1IOSCyaHHz[S=>	NUXrVIZuOjB2OUG0OFA>
NB4	M1HNe2tqdmG\|ZTDBd5NigQ>?	Mli5OUDPxE1?	MorjNlQhcA>?	NGO5ZWdFVVOR	MX;Jcohq[mm2aX;uJI9nKEiGQVOgZZN{\XO\|ZXSgZZMhcW6lcnXhd4UhcW5iYXPleJlt[XSnIIT1ZpVtcW5ibHX2[Yw>	MUmyNFQ6OTR2MB?=
NB4	NIfJTYNHfW6ldHnvckBCe3OjeR?=	NF7icFI2KM7:TR?=	M2H4c\|I1KGh?	M3rkdmROW09?	M3P5U2lv\HWldHnvckBw\iCyMkHXRWYyN0OLUEGg[ZhxemW\|c3nvci=>	M{DmXlIxPDlzNESw
NB4	M1zJXWtqdmG\|ZTDBd5NigQ>?	MlG2OUDPxE1?	MVqyOEBp	NHHUc4RFVVOR	M3fHfGlvcGmkaYTpc44hd2ZiSFTBR{Bie3Onc4Pl[EBieyCrbnPy[YF{\SCrbjDobZN1d26nIFizJIFk\XS7bHH0bY9v	MXqyNFQ6OTR2MB?=
NUGC3	NWDsfXRJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUW5TYdXT0l3ME2yMlk1KM7:TR?=	M3PTZlIxQDVyOUex
A549	MlrTSpVv[3Srb36gRZN{[Xl?	NWnsfW1UPSEQvF2=	NXj1T2hQOyCq	NV73d\|ZMTE2VTx?=	M1ftTWlv\HWldHnvckBw\iCjdYTvdIhi\3liaX6gbJVu[W5iQUW0PUBk\WyuczDhd5Nme3OnZDDhd{BqdmO{ZXHz[UBqdiCOQ{PJTS=>	M2f6TVIxQDV3MkC4
HUT78	NFzkPXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		Mn\1O\|IhcA>?	Mn\6SG1UVw>?	MofNS2k2OD1yLkOg{txO	M1vuO\|IxQDh2MkC4
U937	NF\6OpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NIjBOY84OiCq	M4jHcGROW09?	NX\tUnFST0l3ME2wMlM6KM7:TR?=	NW\DUIVtOjB6OESyNFg>
A431	M3fDU2N6fG:2b4jpZ{BCe3OjeR?=		NFK0cnk4OiCq		MXfDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDBOFMyKGOnbHzzJI93\XKneIDy[ZN{cW6pIFXHSnIhf2m2aDDJR\|UxKG:oIESuNkDPxE1?	NV\HeZlMOjFyOEC2Nlk>
A549	NWfaVWdwS3m2b4TvfIlkKEG\|c3H5		MWq3NkBp		NUj6bmJzS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hSTV2OTDj[YxteyCxdnXy[ZhxemW\|c3nu[{BJTEGFIIfpeIghUUN3MDDv[kAyNjhizszN	NYCzeVJFOjFyOEC2Nlk>
CAL27	NILjVY1EgXSxdH;4bYMhSXO\|YYm=		MlXlO\|IhcA>?		MoHQR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gR2FNOjdiY3XscJMhd3[ncnX4dJJme3OrbnegSWdHWiC5aYToJGlEPTBib3[gN{4zKM7:TR?=	NXXuclk2OjFyOEC2Nlk>
HeLa	NFize\|ZEgXSxdH;4bYMhSXO\|YYm=		NV3COXVlPzJiaB?=		NFqyWGZEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJ\UyjIHPlcIx{KG:4ZYLlfJBz\XO\|aX7nJGhFSUNid3n0bEBKSzVyIH;mJFEvPSEQvF2=	MV2yNVA5ODZ{OR?=
Sf21	MYDLbY5ie2ViQYPzZZk>		NHzYUWo{KGh?		NVy2UG5xUW6qaXLpeIlwdiCxZjDGcIFoKHSjZ3fl[EBpfW2jbjDy[YNwdWKrbnHueEBJTEGFODDlfJBz\XO\|ZXSge4l1cCCLQ{WwJI9nKDFwMjFOwG0>	NE[0b3EzOTB6ME[yPS=>
SKBR3	NVzrfJNxS3m2b4TvfIlkKEG\|c3H5		NVHLSHNbPzJiaB?=		NEDheoVEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBUU0KUMzDj[YxteyCxdnXy[ZhxemW\|c3nu[{BJTVJ{IIfpeIghUUN3MDDv[kAzNjZizszN	NG\aS5kzOTB6ME[yPS=>
SKOV3	MUjDfZRwfG:6aXOgRZN{[Xl?		NXHzNGRvPzJiaB?=		Mo\xR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gV2tQXjNiY3XscJMhd3[ncnX4dJJme3OrbnegTGVTOiC5aYToJGlEPTBib3[gNk4zKM7:TR?=	NVfoVY1sOjFyOEC2Nlk>
COR-L23	MlnGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlK2NVAh\|ryP	MYK3NkBp	M1fnNGROW09?	M163WWdKPTB;MT6xJO69VQ>?	NYn6ZYRtOjFyOEC2OFc>
DU145	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1nJSlExKM7:TR?=	NFfZRoI4OiCq	NF7DR4hFVVOR	NVLEdZJTT0l3ME2xMlA2KM7:TR?=	M1vldFIyODhyNkS3
LoVo	MoLFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGna[FkyOCEQvF2=	NFrqN2U4OiCq	M1TSPGROW09?	M{DKdGdKPTB;MT63JO69VQ>?	NH7OS5QzOTB6ME[0Oy=>
MCR5-SV2	MnXGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIPPdIoyOCEQvF2=	M4jaZ\|czKGh?	MnzPSG1UVw>?	NWTCPYo1T0l3ME2yMlEh\|ryP	MkTGNlExQDB4NEe=
HCT116	MmPsT4lv[XOnIFHzd4F6	Ml;RN\|Ah\|ryP	NEXMOGc{OCCq	NUjQXWVmTE2VTx?=	Mn[xTY5pcWKrdHnvckBw\iCKRFHDOkBie3Onc4Pl[EBieyCrbnT1Z5Rqd25ib3[gZYxxcGFvdIXieYxqdiCjY3X0fYxifGmxbh?=	NYfNcWRyOjFyOEC2OFc>
HCT116	MWHLbY5ie2ViQYPzZZk>	MUezNEDPxE1?	M3m1OFMxKGh?	MWXEUXNQ	NIT0bYtKdmirYnn0bY9vKG:oIFjERWMyKGG\|c3Xzd4VlKGG\|IHnu[JVkfGmxbjDv[kBpcXO2b37lJGg{UzliYXPleJlt[XSrb36=	M32zNVIyODhyNkS3
U937	MlS4T4lv[XOnIFHzd4F6	NYnmTZVpPSEQvF2=	NF3lWYIzPCCq	M2H2[GROW09?	MVfJcohq[mm2aX;uJI9nKGirc4TvcoUh[WOndInseJJidnOoZYLhd4Uh[XO\|ZYPz[YQh[XNiaX7jdoVie2Vib3[gZYNmfHmuYYTpc44hd2ZiaHnzeI9v\SCKMzDheEBMQQ>?	Mnv4NlEzQTJ2OUK=
U937	MmPqT4lv[XOnIFHzd4F6	M1jaTFUh\|ryP	M1nufFI1KGh?	M3XtWGROW09?	NUnkNHUxUW6qaXLpeIlwdiCxZjDobZN1d26nIHHj[ZR6dHS{YX7z[oVz[XOnIHHzd4V{e2WmIHHzJIlv[3KnYYPlJI9nKGGlZYT5cIF1cW:wIH;mJIhqe3SxbnWgTFMh[XRiS{G4	M370OVIyOjl{NEmy
U937	MVvLbY5ie2ViQYPzZZk>	NEHld4c2KM7:TR?=	M16xT\|I1KGh?	MoewSG1UVw>?	NGjSSHdKdmirYnn0bY9vKG:oIHjpd5RwdmViYXPleJltfHKjboPm[ZJie2ViYYPz[ZN{\WRiYYOgbY5kemWjc3Wgc4YheGGwLXHj[ZR6dGG2ZXSgbIl{fG:wZTDIOEBt\X[nbB?=	NEn3NpQzOTJ7MkS5Ni=>
U937	NHGy[lhMcW6jc3WgRZN{[Xl?	NYjEdoxsPSEQvF2=	M4G4VFE2KG2rbh?=	MkDZSG1UVw>?	NI\reppKdmirYnn0bY9vKG:oIHjpd5RwdmViYXPleJltfHKjboPm[ZJie2ViYYPz[ZN{\WRiYYOgbY5kemWjc3Wgc4YhcGm\|dH;u[UBJOyCjY3X0fYxifGmxbjDs[ZZmdA>?	NHXGSmkzOTJ7MkS5Ni=>
A2780	NXPDO2dsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MoL6PVYhcA>?	M{HiOWROW09?	MXfJR\|UxRTFwNkKg{txO	NX2zPFg2OjF4M{S0N\|A>
COLO205	NGrpbZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NUK5fpVYQTZiaB?=	NIKwVXBFVVOR	NYnDOotvUUN3ME2yMlEzKM7:TR?=	NXnQRmRDOjF4M{S0N\|A>
Hep3B	NXjXXIJPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NGDL[VA1QCCq	M133d2ROW09?	MofPS2k2OD1zLkKxJO69VQ>?	MXuyNVcyOjF2Nh?=
GM11272	Ml\HSpVv[3Srb36gRZN{[Xl?	MmjMNVAxKG6P	NF;1d4g4OiCq	NXH4NopCTE2VTx?=	MWHS[YFkfGm4YYTpc44hd2ZiTXXDdFIhdXW2YX70JIV5eHKnc4Ppc44h[XRiMUCgeI8hOTByIH7N	M1HyS\|IyQDRyN{G2
CFBE41o	Ml3mT4lv[XOnIFHzd4F6	M{DCZVUh\|ryP		MXnEUXNQ	NWC2e3RlTG:5bjDy[Yd2dGG2aX;uJI9nKEiGQVO3JIF1KDBwMjD0c{A2KHWP	NH3CeXYzOTl6NEm1PC=>
CFBE41o	NFLCfpRHfW6ldHnvckBCe3OjeR?=	NHW2Z48yKM7:TR?=	MojlNlQhcA>?	MULEUXNQ	MlLMVoV{fG:{YYTpc44hd2ZiQ1\UVkBl\Wy2YV[1NFghdXW2YX70JJRz[W[oaXPrbY5oKHSxIHPlcIwhe3W{ZnHj[UBieyCpbInjc4Zwem2\|	MnPhNlE6QDR7NUi=
DU145	NFjzW3dMcW6jc3WgRZN{[Xl?	MV2yMlUh\|ryP	NIS0XFQzPCCq	NWnNN2kyTE2VTx?=	M4O1dmlvcGmkaYTpc44hd2ZiSFTBR{Bie3Onc4Pl[EBieyC3cILl[5Vt[XSrb36gc4YheDJzd3HmNUBxem:2ZXnuJIV5eHKnc4Ppc44>	M1XFOVIzOjZyMU[2
DU145	M4[4VmtqdmG\|ZTDBd5NigQ>?	MUK1JO69VQ>?	MVSyOEBp	M2PORWROW09?	MnrlTY5pcWKrdHnvckBw\iCKRFHDJIF{e2W\|c3XkJIF{KGirc4TvcoUhUDRiYXPleJlt[XSrb36=	M2Hu[\|IzOjZyMU[2
DU145	M4i2TGtqdmG\|ZTDBd5NigQ>?	MljIOUDPxE1?	MnKxNlQhcA>?	NI\6coFFVVOR	NYHaXJZmUW6qaXLpeIlwdiCxZjDISGFEKGG\|c3Xzd4VlKGG\|IHjpd5RwdmViSEOgbJlx\XKjY3X0fYxifGmxbh?=	NXLWfnRPOjJ{NkCxOlY>
786-0	NGD3WlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M331WlYvOiEQvF2=	MVi3NkBp	NUXWNWdnTE2VTx?=	MUXHTVUxRTNwMjFOwG0>	NWPW[phFOjJ2M{W2Olk>
A498	MlHmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnvqOk4zKM7:TR?=	M{\sW\|czKGh?	MkXFSG1UVw>?	M17MdGdKPTB;MT62JO69VQ>?	MlXJNlI1OzV4Nkm=
A549/ATCC	M4Cwemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlSyOk4zKM7:TR?=	MlrwO\|IhcA>?	M2e1Z2ROW09?	NIHPT3NIUTVyPUGuOkDPxE1?	MWGyNlQ{PTZ4OR?=
ACHN	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MonVOk4zKM7:TR?=	Ml7vO\|IhcA>?	NWrMbpFMTE2VTx?=	NXLpWZkzT0l3ME2xMlMh\|ryP	NFzUZXUzOjR\|NU[2PS=>
BT549	MlXxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEDCc2o3NjJizszN	NHv5fmw4OiCq	MmDHSG1UVw>?	MmHhS2k2OD1zLkOg{txO	MnSxNlI1OzV4Nkm=
EKVX	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYOxUFhUPi5{IN88US=>	MmPSO\|IhcA>?	M4DCb2ROW09?	Mk\4S2k2OD1zLkOg{txO	NFHER3QzOjR\|NU[2PS=>
HCT15	NUmwNmJbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1HxdFYvOiEQvF2=	M{HBXlczKGh?	NFm3PIZFVVOR	Mm[xS2k2OD1{LkWg{txO	M2iwPVIzPDN3Nk[5
HOP92	NWe5dpR6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MluwOk4zKM7:TR?=	M{LxdlczKGh?	NVLuN5M6TE2VTx?=	M2n2OWdKPTB;NDFOwG0>	NWr4VG1lOjJ2M{W2Olk>
IGROV1	Mn\wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVX5UoExPi5{IN88US=>	M{\WeVczKGh?	MlPhSG1UVw>?	M4LiWWdKPTB;MT6zJO69VQ>?	MWGyNlQ{PTZ4OR?=
LOXIMVI	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVOydXc5Pi5{IN88US=>	MlzVO\|IhcA>?	MljjSG1UVw>?	NFzzZWpIUTVyPUGg{txO	NH;WXHQzOjR\|NU[2PS=>
M14	M{LRV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2DsblYvOiEQvF2=	MUS3NkBp	NVS2NnBbTE2VTx?=	NIHr[opIUTVyPUGuN{DPxE1?	NHL2WmYzOjR\|NU[2PS=>
MALME-3M	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn;lOk4zKM7:TR?=	NV7Pcm9nPzJiaB?=	M3PWRWROW09?	MlnxS2k2OD1yLkOyJO69VQ>?	M1XudlIzPDN3Nk[5
MCF10A	NXzJV3Q4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUm2MlIh\|ryP	NGXoeIw1QCCq	MVfEUXNQ	MVjHTVUxRTlwNjFOwG0>	M3e5W\|IzPDN3Nk[5
MDA-MB-435	NVvMRmJzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnLlOk4zKM7:TR?=	NYS4fIpWPzJiaB?=	MlrBSG1UVw>?	MXvHTVUxRTBwNTFOwG0>	M2XyTVIzPDN3Nk[5
MDA-MB-468	NI[4fVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWTkXpZsPi5{IN88US=>	NUjWSXJUPzJiaB?=	NVGwW3BJTE2VTx?=	MVzHTVUxRTBwNkOg{txO	NVH5RppGOjJ2M{W2Olk>
MOLT4	NYfybG5DT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIXDUoo3NjJizszN	M1rofVczKGh?	NGj1e5NFVVOR	MoXmS2k2OD1yLkSg{txO	M1z2WVIzPDN3Nk[5
NCI-ADR-RES	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2CydlYvOiEQvF2=	M3vFcFczKGh?	NGW4R2NFVVOR	NUHwZXRrT0l3ME2wMlE3KM7:TR?=	MYSyNlQ{PTZ4OR?=
NCI-H23	NUDOV4JkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGLF[lc3NjJizszN	M1voNFczKGh?	NIDOR2tFVVOR	MoPrS2k2OD1zIN88US=>	NFLrToczOjR\|NU[2PS=>
NCI-H322M	M{\NN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXS2MlIh\|ryP	M4\LeVczKGh?	NV;x[4djTE2VTx?=	MX\HTVUxRTBwN{mg{txO	NFHMfmMzOjR\|NU[2PS=>
NCI-H460	NVfmZ3R1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVXybplNPi5{IN88US=>	M1TNNFczKGh?	MV3EUXNQ	NWL1ZpJYT0l3ME2wMlc6KM7:TR?=	NWOyWGFqOjJ2M{W2Olk>
NCI-H522	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXO2MlIh\|ryP	NHK1Slk4OiCq	MYrEUXNQ	MU\HTVUxRTBwNTFOwG0>	NH;FUY8zOjR\|NU[2PS=>
OVCAR3	Mlf0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1XoRVYvOiEQvF2=	MXq3NkBp	M{LleWROW09?	MWjHTVUxRTFwMzFOwG0>	NGTxUZQzOjR\|NU[2PS=>
OVCAR4	NILIVJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3ThNFYvOiEQvF2=	NX30bFhXPzJiaB?=	MVzEUXNQ	NGOwU5FIUTVyPUSg{txO	NHX4NYgzOjR\|NU[2PS=>
OVCAR5	MlLnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4PxdVYvOiEQvF2=	MlPFO\|IhcA>?	M4nob2ROW09?	MWLHTVUxRTBwN{mg{txO	MmflNlI1OzV4Nkm=
OVCAR8	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlnuOk4zKM7:TR?=	M3Pib\|czKGh?	M1rHW2ROW09?	MlSzS2k2OD1yLkWg{txO	M{HZPVIzPDN3Nk[5
RXF393	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVrxcW1SPi5{IN88US=>	NFTTT4w4OiCq	NYHiXVRkTE2VTx?=	M1fDeGdKPTB;MT6zJO69VQ>?	MnrWNlI1OzV4Nkm=
SF268	NX7jdmJ4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mny1Ok4zKM7:TR?=	MWi3NkBp	MXjEUXNQ	MWnHTVUxRTFwNjFOwG0>	NUjQb4ZNOjJ2M{W2Olk>
SF295	NVvFcIw2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnntOk4zKM7:TR?=	NFHUZ244OiCq	M1nyNWROW09?	MYrHTVUxRTFwNjFOwG0>	NGezR2YzOjR\|NU[2PS=>
SF539	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFX1XYw3NjJizszN	MXu3NkBp	MX3EUXNQ	NXXveolET0l3ME2yJO69VQ>?	M{DwZ\|IzPDN3Nk[5
SK-MEL-2	M3PlOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVnlXlR[Pi5{IN88US=>	M1XYVVczKGh?	MkL0SG1UVw>?	NVLJcJM2T0l3ME2xMlMh\|ryP	MWqyNlQ{PTZ4OR?=
SK-MEL-28	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlnqOk4zKM7:TR?=	NGnNZYQ4OiCq	MV\EUXNQ	MmnNS2k2OD1zIN88US=>	NYf5OoNrOjJ2M{W2Olk>
SK-MEL-5	M2OzOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXy2MlIh\|ryP	Ml;PO\|IhcA>?	MkS2SG1UVw>?	MVzHTVUxRTBwNkOg{txO	NX:2V5dtOjJ2M{W2Olk>
SKOV3	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGLCN\|U3NjJizszN	M{DEU\|czKGh?	NHHDdnhFVVOR	NXj0V5hWT0l3ME2xJO69VQ>?	NH;CUHUzOjR\|NU[2PS=>
SN12C	M3vYSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH\acpk3NjJizszN	MXS3NkBp	NVXmbVBVTE2VTx?=	MWjHTVUxRTJizszN	MY[yNlQ{PTZ4OR?=
SNB19	Mn7CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mlv4Ok4zKM7:TR?=	MY[3NkBp	MmHJSG1UVw>?	MU\HTVUxRTBwNkOg{txO	M1jLOVIzPDN3Nk[5
SNB75	M2CyRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIPqUVQ3NjJizszN	NWXkNWp1PzJiaB?=	NWnJNVVvTE2VTx?=	MYLHTVUxRTBwN{mg{txO	MXqyNlQ{PTZ4OR?=
SR	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFPHWZQ3NjJizszN	NWG0RlNZPzJiaB?=	NXHqRlFWTE2VTx?=	NF:xWIlIUTVyPUCuOEDPxE1?	M2f0TFIzPDN3Nk[5
T47D	NWnobo9nT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF23PZU3NjJizszN	Mkm0O\|IhcA>?	NF3ESW5FVVOR	NVnZepRQT0l3ME2wMlUh\|ryP	NH7yXWMzOjR\|NU[2PS=>
TK10	NUXEPYdLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVy2O4ZIPi5{IN88US=>	NGW0VXA4OiCq	NF[xV3BFVVOR	MnvNS2k2OD1yLk[zJO69VQ>?	MorqNlI1OzV4Nkm=
UACC257	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGPsSXo3NjJizszN	NXrk[\|FoPzJiaB?=	M3\FOmROW09?	NX7DUHB5T0l3ME2wMlUh\|ryP	MonINlI1OzV4Nkm=
UACC62	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWG2MlIh\|ryP	NXK1dWtZPzJiaB?=	NWjsPJJPTE2VTx?=	M4TGZmdKPTB;MD60JO69VQ>?	MojINlI1OzV4Nkm=
UO31	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVS2MlIh\|ryP	MUW3NkBp	M33sUGROW09?	NUDDcIM3T0l3ME2wMlUh\|ryP	NITTVGkzOjR\|NU[2PS=>
Hep3B	NVizVYhST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MlnmOFghcA>?	M1:1OmROW09?	NFTuWG1IUTVyPUCuOlkh\|ryP	Mn3oNlI1Ozl6NkO=
BE(2)-C	Mmf2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NH7KcYs4OiCq	M4f6OmROW09?	NGPpOpFKSzdyPUKg{txO	M3nUd\|IzQTN{M{G2
Bel7402	MmDDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MkjVO\|IhcA>?	NX\2UZl{TE2VTx?=	MYTHTVkxRTF5IN88US=>	MY[yN\|A3OTN5Nh?=
Bel7404	MmPTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MoTIO\|IhcA>?	NGLMfFBFVVOR	MmTvS2k6OD1zODFOwG0>	M1TMW\|I{ODZzM{e2
BGC823	Mm\oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M2fFNlczKGh?	NVHU[3l{TE2VTx?=	NFXHNZBIUTlyPUeuOUDPxE1?	NXHQcVJkOjNyNkGzO\|Y>
MGC803	MnjES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MnT5O\|IhcA>?	NEDR[5ZFVVOR	NFywcJVIUTlyPUGwMlgh\|ryP	MWqyN\|A3OTN5Nh?=
SGC7901	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NUCye5RHPzJiaB?=	M3fMPWROW09?	NFntd3hIUTlyPUmuOEDPxE1?	NH20N5EzOzB4MUO3Oi=>
SKHEP1	NInibJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NV7HRmp1PzJiaB?=	MUXEUXNQ	M{XodmdKQTB;MUeg{txO	MUWyN\|A3OTN5Nh?=
SMMC7721	NF\oWGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NHTpWZc4OiCq	NVnZVplkTE2VTx?=	MXnHTVkxRTJyIN88US=>	NIryd4ozOzB4MUO3Oi=>
NUGC3	M2TrfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWOxNEDPxE1?			NEjofmtIUT1{Lkm0JO69VQ>?	MYmyN\|E3OzN\|Mh?=
A2780 CisR	MXnLbY5ie2ViQYPzZZk>		M4rYTlE5KGh?		NV;2dGx3UW6qaXLpeIlwdiCxZjDISGFEKHerdHigTWM2OCCxZjCwMlQ1KM7:TR?=	M1;oUVI{OjV{NkCz
CAL27 sens	NYe1NJgzU2mwYYPlJGF{e2G7		NFLs[3MyQCCq		MoLNTY5pcWKrdHnvckBw\iCKRFHDJJdqfGhiSVO1NEBw\iByLkO2JO69VQ>?	NU\PdmhmOjN{NUK2NFM>
CAL27 CisR	NGfr[pJMcW6jc3WgRZN{[Xl?		M4P3TVE5KGh?		NI\Qc5lKdmirYnn0bY9vKG:oIFjERWMhf2m2aDDJR\|UxKG:oIECuOlEh\|ryP	MX2yN\|I2OjZyMx?=
KYSE-510 CisR	M2rpcWtqdmG\|ZTDBd5NigQ>?		M2PrR\|E5KGh?		MVrJcohq[mm2aX;uJI9nKEiGQVOge4l1cCCLQ{WwJI9nKDBwNUmg{txO	M1zlOlI{OjV{NkCz
KYSE-510 sens	MUHLbY5ie2ViQYPzZZk>		NITHeIIyQCCq		MofBTY5pcWKrdHnvckBw\iCKRFHDJJdqfGhiSVO1NEBw\iByLkeg{txO	M3q4N\|I{OjV{NkCz
MDA-MB-231 sens	MnTPT4lv[XOnIFHzd4F6		MV[xPEBp		MX;Jcohq[mm2aX;uJI9nKEiGQVOge4l1cCCLQ{WwJI9nKDBwNkGg{txO	NU\ZN4VMOjN{NUK2NFM>
MDA-MB-231 CisR	M2rkbmtqdmG\|ZTDBd5NigQ>?		MX6xPEBp		NVvKN4Q3UW6qaXLpeIlwdiCxZjDISGFEKHerdHigTWM2OCCxZjCwMlYyKM7:TR?=	NVnzXFlFOjN{NUK2NFM>
ES2	M1uyc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NHPxT2s1QCCq	MVXEUXNQ	NUGwc5pEUUN3ME2xNk44KM7:TR?=	M3zZclI{PDl\|NES5
MDA-MB-231	MXTLbY5ie2ViQYPzZZk>	NVjGVnpqOTBizszN	MlK2N\|AhdWmw	MV;EUXNQ	MVfJcohq[mm2aX;uJI9nKEiGQVOyZS=>	NGGzWnYzOzR7M{S0PS=>
MDA-MB-231	NHTTXXdMcW6jc3WgRZN{[Xl?	NIDwNoQyKM7:TR?=	Mlz0NlQhcA>?	NETMVphFVVOR	M1;IcGlvcGmkaYTpc44hd2ZiSFTBR\|Yh[XO\|ZYPz[YQh[XNiYXPleJlt[XSrb36gcIV3\Wy\|IH;mJJR2[nWuaX6=	NYGzb29[OjN2OUO0OFk>
HS68	M1TPWmN6fG:2b4jpZ{BCe3OjeR?=	M{f5OlExKM7:TR?=	MVS3NkBp	MVXEUXNQ	NEj3dlJKSzVyPUSuOkDPxE1?	NUn4PIpWOjN3N{C1OFI>
MEF	MlLSR5l1d3SxeHnjJGF{e2G7	MUGxNEDPxE1?	MVu3NkBp	NGPuO4FFVVOR	NV3kbIJqUUN3ME20MlQh\|ryP	MlnSNlM2PzB3NEK=
BGC823	NVnFV3dYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NXrn[GZ3TE2VTx?=	MnfQS2k2OD1\|LkC5JO69VQ>?	NWTHSVR[OjN4MEG3NFY>
High5	NXqwVGt2U2mwYYPlJGF{e2G7		NH;Ce2YzPCCq		M1TkPGlvcGmkaYTpc44hd2ZiaIXtZY4hemWlb33ibY5idnRiSFTBR\|Yhf2m2aDDJR\|UxKG:oIECuNFkh\|ryP	NV\LfWlmOjN4MEK1NlM>
High5	MXzLbY5ie2ViQYPzZZk>		NXL5RphpOjRiaB?=		Mnu1TY5pcWKrdHnvckBw\iCqdX3hckBz\WOxbXLpcoFvfCCKRFHDNUB4cXSqIFnDOVAhd2ZiMD6xNkDPxE1?	M2rPc\|I{PjB{NUKz
High5	NYrwWIxGU2mwYYPlJGF{e2G7		NWjDdnFkOjRiaB?=		NFzvWnBKdmirYnn0bY9vKG:oIHj1cYFvKHKnY3;tZolv[W62IFjERWM{KHerdHigTWM2OCCxZjCwMlE4KM7:TR?=	NUfoRlBPOjN4MEK1NlM>
A549	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NXvJXpMyTE2VTx?=	MkKwTWM2OD1zLkC3PUDPxE1?	MV[yN\|Y1PDJzMB?=
HCT116	MlLQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NYm1ZldTTE2VTx?=	NGTWWXlKSzVyPUCuO\|U4KM7:TR?=	MVmyN\|Y1PDJzMB?=
K562	NGHLb4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MWrEUXNQ	NYSwemNCUUN3ME2wMlY1PSEQvF2=	NVTTbmttOjN4NESyNVA>
GBC-SD	NVTVVWJsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3HkU\|Uh\|ryP	MYC3NkBp	NF3wRXpFVVOR	MXzJR\|UxRTF2Lkig{txO	NGfsS3QzOzdyN{K2NC=>
HGC27	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mli2OUDPxE1?	NELRZYo4OiCq	Mn\XSG1UVw>?	MYfJR\|UxRTVwNDFOwG0>	MnPZNlM4ODd{NkC=
HL60	MlLJT4lv[XOnIFHzd4F6	M{fG[lUh\|ryP	MViyOEBp	MWrEUXNQ	NHLMWFJKdmirYnn0bY9vKG:oIFjERWM>	NFixVVEzOzdyN{K2NC=>
Vero	NHvJXVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NXXTVGFjPzJiaB?=	NIixbW5FVVOR	MlvrTWM2OD1yLkmg{txO	M13tdFI{Pzh4NEWy
NCI60	NHLsbolEgXSxdH;4bYMhSXO\|YYm=		MmnlOFghcA>?	NGX4V5pFVVOR	NVLEZW9oT0l;MD61N{DPxE1?	M2jvNFI1ODF3M{K3
SW620	NUXVe4s1S3m2b4TvfIlkKEG\|c3H5		NXLzflRVPDhiaB?=	M{L4ZmROW09?	MUfHTV0xNjV2IN88US=>	MkXzNlQxOTV\|Mke=
U251	M4PRU2N6fG:2b4jpZ{BCe3OjeR?=		MYW0PEBp	MV\EUXNQ	NE\TdFZIUT1zLkWzJO69VQ>?	M3\JSFI1ODF3M{K3
KM12	NGfYOW1EgXSxdH;4bYMhSXO\|YYm=		NYPpNXl1PDhiaB?=	MnW1SG1UVw>?	MoXoS2k:OS56ODFOwG0>	MYiyOFAyPTN{Nx?=
Hs578T	MX3DfZRwfG:6aXOgRZN{[Xl?		MYK0PEBp	NWPXdYJSTE2VTx?=	NYfK[3RkT0l;ND64N{DPxE1?	Mm\kNlQxOTV\|Mke=
MDA-MB-231	MlTLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M336flQ5KGh?		MUTJR\|UxRTBwMU[g{txO	MmnPNlQxQTVyMU[=
MCF7	NWTIN5hUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MlPzOFghcA>?		MVHHTV0xNjR3IN88US=>	M2rMeFI1OTF7NUW1
MDA-MB-435	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NWHuPWVLPDhiaB?=		NILHb2pIUT1yLki4JO69VQ>?	NYjQOVVjOjRzMUm1OVU>
AsPC1	NGTrd29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXezNEDPxE1?	MX[0PEBp	NUXXXpFJTE2VTx?=	MlnsTWM2OD1\|Lk[2JO69VQ>?	NGT1eowzPDF6NUO3PC=>
Jurkat E6.1	NXjNeJhtU2mwYYPlJGF{e2G7		MWSyJIg>	MVrEUXNQ	M2PQbWlvcGmkaYTpc44hd2ZiSFTBR\|Qhf2m2aDDJR\|UxKG:oIECuNFQh\|ryP	M13sflI1OjZzOE[y
KG1	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NEnwTHk1QCCq		M130emlEPTB;MT6xOUDPxE1?	MW[yOFUzPTByMx?=
HEL	NIPJVnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M2LLZ\|Q5KGh?	NVTpRXVNTE2VTx?=	NFLhW3VKSzVyPUCuOFkh\|ryP	MWeyOFY6PDB3NR?=
HSC3	MlqzR5l1d3SxeHnjJGF{e2G7		Mn70NVIhcA>?	Mkn5SG1UVw>?	MnO3TWM2OD1yLkexJO69VQ>?	NFrhflAzPDd4NkW2NC=>
HT-29	NHvWcYJEgXSxdH;4bYMhSXO\|YYm=		MU[xNkBp	NGnjWmpFVVOR	MYnJR\|UxRTBwN{Kg{txO	MYOyOFc3PjV4MB?=
KB	NHfye5BEgXSxdH;4bYMhSXO\|YYm=		MlLsNVIhcA>?	NYD5dXg1TE2VTx?=	MV7JR\|UxRTBwN{Wg{txO	MVGyOFc3PjV4MB?=
H460	NFv0[FFEgXSxdH;4bYMhSXO\|YYm=		M2LVWlEzKGh?	MV7EUXNQ	M3fzb2lEPTB;MD64NkDPxE1?	M1\MS\|I1PzZ4NU[w
MONE1	MYLDfZRwfG:6aXOgRZN{[Xl?		M1LGc\|EzKGh?	M2n4cGROW09?	NVOzUIE{UUN3ME2xMlE5KM7:TR?=	Ml\xNlQ4PjZ3NkC=
MKN45	MX;DfZRwfG:6aXOgRZN{[Xl?		M4i4VFEzKGh?	MXTEUXNQ	NFXCWJRKSzVyPUGuNlUh\|ryP	NIH0OlEzPDd4NkW2NC=>
TSGH	MW\DfZRwfG:6aXOgRZN{[Xl?		M1TPbFEzKGh?	MnLlSG1UVw>?	NXziVoNZUUN3ME2yMlA6KM7:TR?=	M3LRR\|I1PzZ4NU[w
HL60	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MoLHO\|IhcA>?	M335d2ROW09?	MmjqS2k2OD1yLkmzJO69VQ>?	NETiN44zPDlyMEWwNC=>
HEK293	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NFHLS5g4OiCq	MWLEUXNQ	NWPS[mloT0l3ME2xN{DPxE1?	MoHiNlQ6ODB3MEC=
Jurkat	Mmi2R5l1d3SxeHnjJGF{e2G7	NEjWXVgyODBizszN	MUe3NkBp		NHTNd4NIUTVyPUCuPUDPxE1?	MlLENlQ6ODB5NEO=
GM15850	M2LWXWtqdmG\|ZTDBd5NigQ>?	NGHwOXEzNjVizszN	NVvCc4NIQTZiaB?=	MX7EUXNQ	MkfW[I9meyCwb4SgbY5pcWKrdDDISGFEKGG\|c3Xzd4VlKGG\|IHnuZ5Jm[XOnIHnuJIhqe3SxbnWgTFMhdHm\|aX7lJFE1KGGlZYT5cIF1cW:wIH;mJGZZViCpZX7l	M3Lab\|E3QTJzM{[3
GM15850	MYjLbY5ie2ViQYPzZZk>	MUOyMlUh\|ryP	MoizPVYhcA>?	Ml3xSG1UVw>?	NF36VYZld2W\|IH7veEBqdmirYnn0JGhFSUNiYYPz[ZN{\WRiYYOgbY5kemWjc3WgbY4hcGm\|dH;u[UBJPCCueYPpcoUhPSCjY3X0fYxifGmxbjDv[kBHYE5iZ3Xu[S=>	MUKxOlkzOTN4Nx?=
GM15850	NXK1WIJYU2mwYYPlJGF{e2G7	MUeyMlUh\|ryP	NIfPe5E6PiCq	MoXxSG1UVw>?	Mlnm[I9meyCwb4SgbY5pcWKrdDDISGFEKGG\|c3Xzd4VlKGG\|IHnuZ5Jm[XOnIHnuJIhqe3SxbnWgTFQhdHm\|aX7lJFEzKGGlZYT5cIF1cW:wIH;mJGZZViCpZX7l	NHLtenYyPjl{MUO2Oy=>
GM15850	NV:4WoZvU2mwYYPlJGF{e2G7	MnjzNk42KM7:TR?=	M1XKbVk3KGh?	NVTlOllYTE2VTx?=	M17VcoRw\XNibn;0JIlvcGmkaYSgTGRCSyCjc4Pld5Nm\CCjczDpcoNz\WG\|ZTDpckBpcXO2b37lJGg{KGy7c3nu[UA6KGGlZYT5cIF1cW:wIH;mJGZZViCpZX7l	MUexOlkzOTN4Nx?=
GM15850	MUjLbY5ie2ViQYPzZZk>	NEDDclczNjVizszN	MUe5OkBp	M{i3[WROW09?	M3zX[oRw\XNibn;0JIlvcGmkaYSgTGRCSyCjc4Pld5Nm\CCjczDpcoNz\WG\|ZTDpckBpcXO2b37lJGg1KGy7c3nu[UA5KGGlZYT5cIF1cW:wIH;mJGZZViCpZX7l	MlHDNVY6OjF\|Nke=
GM15850	NGLycmdMcW6jc3WgRZN{[Xl?	MnHLNk42KM7:TR?=	NFz6OXM6PiCq	MmW2SG1UVw>?	Mm\K[I9meyCwb4SgbY5pcWKrdDDISGFEKGG\|c3Xzd4VlKGG\|IHnuZ5Jm[XOnIHnuJIhqe3SxbnWgTFQhdHm\|aX7lJFE3KGGlZYT5cIF1cW:wIH;mJGZZViCpZX7l	NIi2dnkyPjl{MUO2Oy=>
GM15850	NHr4cXhHfW6ldHnvckBCe3OjeR?=	M2PndVUh\|ryP	MkTrNVIhcA>?	MWTEUXNQ	NF[yT3lp[XNibn:g[YZn\WO2IH;uJGZZViCvUl7BJIV5eHKnc4Ppc44>	MkX6NVY6OjF\|Nke=
U937	M1jE[WtqdmG\|ZTDBd5NigQ>?	M4jaOVUh\|ryP	MlXlNlQhcA>?	NHm0flhFVVOR	NHXZNoZp[XNibn:g[YZn\WO2IH;uJIFteGijIIT1ZpVtcW5iYXPleJlt[XSrb36=	NH;PXmcyPzR2N{e1NC=>
U937	MnnDT4lv[XOnIFHzd4F6	NUHSbI9WOSEQvF2=	NFjnNXAzPCCq	M3K2U2ROW09?	NILt[\|Jp[XNibn:g[YZn\WO2IH;uJIFteGijIIT1ZpVtcW5iYXPleJlt[XSrb36=	M{PWW\|E4PDR5N{Ww
PANC1	NVPNeop6TnWwY4Tpc44hSXO\|YYm=	MYGxJO69VQ>?	M3frVFI1KGh?		Mnny[I9meyCwb4SgbY5kemWjc3WgbY4heDJ5a3nwNUBo\W6nIHX4dJJme3Orb36=	M4mxb\|E4PTh6N{S0
PANC1	NG\LZW5HfW6ldHnvckBCe3OjeR?=	NY\EXpNtOSEQvF2=	Mmn3OFghKGh?		NXvocm5p\G:nczDuc5QhcW6lcnXhd4UhcW5icEK3b4lxOSCpZX7lJIV5eHKnc4Ppc44>	NWDuWVdsOTd3OEi3OFQ>
Caco-2	NILTe21HfW6ldHnvckBCe3OjeR?=	MUS1JO69VQ>?	NGjC[nozPCCq	NX3OOVZVTE2VTx?=	NUnq[pg{\G:nczDuc5QhcW6mdXPlJHAzOVeDRkGg[4Vv\SCneIDy[ZN{cW:w	NFrBXWMzODF2M{i0NC=>
SCC4	NV7j[m1ZTnWwY4Tpc44hSXO\|YYm=	M1:yVFEh\|ryP	NGH0WmQyOCCvaX6=	NXvwNYU3TE2VTx?=	NEXwbFdp[XNibn:gZYdwdmm\|dDDhZ5Rqfmm2eTDheEBXTFJiYYPz[ZN{\WRiYYOgbY5lfWO2aX;uJI9nKEO\UEK0JIdmdmViZYjwdoV{e2mxbh?=	MXmyNFQ2OjJ{NR?=
A549	NWixcngzTnWwY4Tpc44hSXO\|YYm=	MVO1JO69VQ>?	MXezJIg>	NUG1Uml4TE2VTx?=	NWC3RoNi\G:nczDuc5QhcW6mdXPlJIF2fG:yaHHnfUBie3Onc4Pl[EBieyCrbnPy[YF{\SCrbjDMR\|NKUQ>?	M4C3VVIxQDV3MkC4
HCT116	MYHLbY5ie2ViQYPzZZk>	MXmwMlMh\|ryP	M4LSSFMxKGh?	M3[4N2ROW09?	M{TGXoRw\XNibn;0JIlvcGmkaYSgTGRCSzFiYYPz[ZN{\WRiYYOgbY5lfWO2aX;uJI9nKGirc4TvcoUhUDONOTDhZ4V1gWyjdHnvci=>	NUnrfGFmOjFyOEC2OFc>
HepG2	MV\GeY5kfGmxbjDBd5NigQ>?	NY\4XZYxOTBizszN	NUniT3kxOjRiaB?=	NYC2UnROTE2VTx?=	NV\vXJVL\G:nczDuc5QhcW6mdXPlJIFxd3C2b4Ppd{Bie3Onc4Pl[EBieyCqeYDldoFk\XS7bHH0bY9vKG:oIIC1Ny=>	MmHvNlE2PDh3OEK=
GM11272	NIW0WmZHfW6ldHnvckBCe3OjeR?=	NWLoVJJpOC5zIN88US=>	NIPUXYE4OiCq	NVvlXJVPTE2VTx?=	NHfDNXhld2W\|IH7veEBz\WGldHn2ZZRmKE2nQ4CyJI12fGGwdDDlfJBz\XO\|aX;u	MY[yNVg1ODdzNh?=
MDA-MB-231	M376NGtqdmG\|ZTDBd5NigQ>?	MmewNVAh\|ryP	NUTYW2Q6PSCvaX6=	M2r0U2ROW09?	MVfkc4V{KG6xdDDpcohq[mm2IFjERWMz[Q>?	NHTGSnYzOzR7M{S0PS=>
MDA-MB-231	NYf5d4VxU2mwYYPlJGF{e2G7	MXuxJO69VQ>?	M2PacVI1KGh?	MVzEUXNQ	NI\xZYZld2W\|IH7veEBqdmirYnn0JGhFSUN4IHHzd4V{e2WmIHHzJIFk\XS7bHH0bY9vKGyndnXsd{Bw\iC2dXL1cIlv	NEDkXJIzOzR7M{S0PS=>
K562	NFH2SJlMcW6jc3WgRZN{[Xl?				NWXLeHpu\G:nczDuc5QhcW6qaXLpeEBJTEGF	M{LLPFI{PTlzMUGx
Jurkat	MWDDfZRwfG:6aXOgRZN{[Xl?	MoriNlAh\|ryP	M2W1TFczKGh?	MlK4SG1UVw>?	MYLuc{BkgXSxdH;4bYNqfHliYYPz[ZN{\WRiYYOg[5Jwf3SqIHnubIljcXSrb36=	MUOyOFMxPDN2OB?=
HCT116	M2XqbmFxd3C2b4Ppd{BCe3OjeR?=	M13FeVMh\|ryP	MmjwNlQhcA>?	NFvn[G9FVVOR	M4jXToRw\XNibn;0JIlv\HWlZTDhdI9xfG:\|aYOgZZN{\XO\|ZXSgZZMhcW6lcnXhd4UhcW5icEWzJJBzd3SnaX6gcIV3\Wx?	M2PCVFI1PzZ4NU[w
KASUMI-1	M2nhNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHX4eXZKSzVyPUm5MlE4KG6P	M1v4fnNCVkeHUh?=
KARPAS-45	MnzNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHf0TnpKSzVyPUG3N{45QSCwTR?=	Mm\UV2FPT0WU
BHT-101	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnTNTWM2OD1{NESuNVghdk1?	NUD3R5A6W0GQR1XS
H9	NGTUeVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkfmTWM2OD1{NUWuNFQhdk1?	M{XsSHNCVkeHUh?=
PA-1	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWfJR\|UxRTJ6Nj6yOkBvVQ>?	NXGzNW97W0GQR1XS
NEC8	Mny4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4fEO2lEPTB;Mki5MlM5KG6P	MV3TRW5ITVJ?
MHH-PREB-1	NIjtRWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnvvTWM2OD1{OUSuOVMhdk1?	MXrTRW5ITVJ?
NB7	MnPjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NECwPFdKSzVyPUO0OU44PCCwTR?=	NHPBZmlUSU6JRWK=
A3-KAW	MmLZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4T5PWlEPTB;NECwMlU6KG6P	M1\QZ3NCVkeHUh?=
NB69	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUDF[4FEUUN3ME20NVEvPzFibl2=	MV7TRW5ITVJ?
EoL-1-cell	NHXyUJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2TEOmlEPTB;NEW0NlUhdk1?	Mo\tV2FPT0WU
CHP-212	MmjOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkPITWM2OD12NUeuOVMhdk1?	NX\3dJc6W0GQR1XS
C2BBe1	NFHjXnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3K3TWlEPTB;NEeyMlE6KG6P	NVHHblA3W0GQR1XS
697	M4Xjd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1nVPGlEPTB;NEezMlQyKG6P	NWjGNFBzW0GQR1XS
BCPAP	M{mzbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmjoTWM2OD13MEGuOFIhdk1?	M4CycnNCVkeHUh?=
L-363	NU[zepJlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoLmTWM2OD13MEOuNUBvVQ>?	M3nUUnNCVkeHUh?=
ES8	NIrvT2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3vxU2lEPTB;NUKzMlU{KG6P	NH;ZcpdUSU6JRWK=
BE-13	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWrmUpRRUUN3ME21NlYvQTZibl2=	M1H0e3NCVkeHUh?=
CTB-1	NILURZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoHDTWM2OD13M{euPVIhdk1?	NF:wWZlUSU6JRWK=
HD-MY-Z	NX3nRVBpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV3JR\|UxRTV\|OD6xN{BvVQ>?	M2rLcHNCVkeHUh?=
NKM-1	M3zUZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkLRTWM2OD13NESuNlchdk1?	MlzSV2FPT0WU
NCI-H720	M3\Zcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlrkTWM2OD13NkCuNVghdk1?	MWHTRW5ITVJ?
KY821	NX3mXI9QT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MonZTWM2OD13NkOuNlUhdk1?	M1vscXNCVkeHUh?=
OVCAR-5	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEnCeFZKSzVyPUW3Ok4yOSCwTR?=	Ml7BV2FPT0WU
CTV-1	MlPBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVLJR\|UxRTV6MT61OkBvVQ>?	NUnHPYJNW0GQR1XS
P12-ICHIKAWA	MkjWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUTrZ2p{UUN3ME21PVYvPTFibl2=	NH;HVoJUSU6JRWK=
DB	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVLvXG5YUUN3ME21PVgvPTdibl2=	M1f2XnNCVkeHUh?=
CHL-1	MmTUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnvaTWM2OD14NEKuNFghdk1?	NYCzXG5JW0GQR1XS
A4-Fuk	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoDjTWM2OD14NESuPVEhdk1?	MnzoV2FPT0WU
MV-4-11	M2\ZS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYfJR\|UxRTZ3OT6xJI5O	MYjTRW5ITVJ?
RPMI-8226	NYnHVYdrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGfuNXFKSzVyPU[3PE4yQCCwTR?=	NXPESYdXW0GQR1XS
NB14	MmDwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXviVnlVUUN3ME22PVYvQTVibl2=	NXTqSXo1W0GQR1XS
DOHH-2	NETBc2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3nyRmlEPTB;N{C2MlY5KG6P	MVXTRW5ITVJ?
D-423MG	MlPxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXzJR\|UxRTdyNj64PUBvVQ>?	M323eXNCVkeHUh?=
D-283MED	NIHCeY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVnPfYVZUUN3ME23NVQvOTRibl2=	NYD6SXVGW0GQR1XS
ES1	NUPR[GliT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUHJR\|UxRTd{ND60JI5O	MmnOV2FPT0WU
GOTO	M4LycGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWfJR\|UxRTd{OT6xNkBvVQ>?	MUfTRW5ITVJ?
NCI-H209	NYTBZYdwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NX21TFJZUUN3ME23NlkvQSCwTR?=	NGn2S\|FUSU6JRWK=
MOLT-13	M{f2V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NG\kdnFKSzVyPUezPE46QCCwTR?=	MlfpV2FPT0WU
ATN-1	M175Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlLsTWM2OD15NECuNlghdk1?	NX;oOoNXW0GQR1XS
DU-4475	MnfqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWTJR\|UxRTd3MT65NUBvVQ>?	NX\1UllqW0GQR1XS
NB10	M3:zWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{TCWGlEPTB;N{WxMlkzKG6P	NFLmXZVUSU6JRWK=
KG-1	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NI[3WFlKSzVyPUe3OU41PSCwTR?=	MkTlV2FPT0WU
MOLT-4	Mk\4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHjjWHZKSzVyPUe4O{41PiCwTR?=	NUOw[WxCW0GQR1XS
TE-1	NXLrXJBDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVLJR\|UxRTd7MT6xJI5O	NVjKR2lvW0GQR1XS
SBC-1	M32wbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVzJR\|UxRTd7Mz64OEBvVQ>?	MYrTRW5ITVJ?
HEL	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXjJR\|UxRThyNj6wPEBvVQ>?	NHL0bpRUSU6JRWK=
SK-MEL-2	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnK3TWM2OD16MEmuOFQhdk1?	M3L0NnNCVkeHUh?=
KU812	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWnJR\|UxRThzMz6xJI5O	NGrnUo9USU6JRWK=
RPMI-8866	MorMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYr5SoxiUUN3ME24NVMvPjdibl2=	M3zI[nNCVkeHUh?=
ALL-PO	NHL6d45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MW\JR\|UxRThzND62OkBvVQ>?	M3Psd3NCVkeHUh?=
LU-139	NEXh[XpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{G5cWlEPTB;OEKyMlg3KG6P	MkjIV2FPT0WU
RS4-11	NYi4ZW1TT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2C5U2lEPTB;OEOyMlQ2KG6P	MnXIV2FPT0WU
EW-18	NIrERm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NELpXHZKSzVyPUizNk46PiCwTR?=	MVPTRW5ITVJ?
P30-OHK	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXXXcVhtUUN3ME24N\|UvPyCwTR?=	NVnjSJZ4W0GQR1XS
D-566MG	NIrlb5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MljMTWM2OD16M{iuOlIhdk1?	NUnPN4U6W0GQR1XS
HSC-4	NH3qUGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnvSTWM2OD16NE[uOVEhdk1?	M3fJfnNCVkeHUh?=
QIMR-WIL	M4rzTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnrtTWM2OD16NkKuNFMhdk1?	M3f3e3NCVkeHUh?=
SW954	NVLCb3JuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWTuOpRbUUN3ME24OlMvOTZibl2=	NUHZWJNiW0GQR1XS
HGC-27	NFXaemtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoX6TWM2OD16N{KuN\|Qhdk1?	NGPS[lFUSU6JRWK=
HH	M4WzXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWrVRYdJUUN3ME24PVQvOTJibl2=	MYTTRW5ITVJ?
KE-37	NGfaWHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{HoUWlEPTB;OEm0MlYzKG6P	MUXTRW5ITVJ?
SK-N-DZ	MnrRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHSyfGJKSzVyPUmwNE41OyCwTR?=	MWPTRW5ITVJ?
J-RT3-T3-5	NF;QZXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2DkcGlEPTB;OUGwMlQ6KG6P	MXrTRW5ITVJ?
A427	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkPjTWM2OD17MkCuPFQhdk1?	MlvWV2FPT0WU
ECC10	NFSwWJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHy2S2RKSzVyPUm0OU45PyCwTR?=	M1m2S3NCVkeHUh?=
EW-1	M{frO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIfnTJlKSzVyPUm0O{4zPiCwTR?=	NYi4eVY6W0GQR1XS
MIA-PaCa-2	Ml;iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NI\LNHZKSzVyPUm0PU4yOiCwTR?=	MYLTRW5ITVJ?
HCC2218	M3;nOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWLlZYkyUUN3ME25OVgvPDhibl2=	NWDXdpVEW0GQR1XS
HAL-01	MnXIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NITEdZpKSzVyPUm2PE4xPCCwTR?=	MYLTRW5ITVJ?
RD	NFrhWYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVHJR\|UxRTl5ND60OUBvVQ>?	MnjNV2FPT0WU
SK-N-AS	M2LUNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M37IfmlEPTB;OUi4MlEhdk1?	Ml3RV2FPT0WU
ML-2	M{fYZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWGzZ\|BmUUN3ME2xMlAxPDB5IN88US=>	NIrUOZhUSU6JRWK=
MEL-HO	NWfIZZFNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHnYfpJKSzVyPUGuNFA2QDJizszN	NUT2WXREW0GQR1XS
MS-1	NWG4OHM2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmnSTWM2OD1zLkCwOlE4KM7:TR?=	NYLxeY1wW0GQR1XS
NCI-SNU-1	MmDNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWDJR\|UxRTFwMEKzN\|Eh\|ryP	NEe3RYZUSU6JRWK=
8505C	NELVTmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV7XSIxCUUN3ME2xMlAzOzNzIN88US=>	MkLPV2FPT0WU
MN-60	NXqxZ3ZqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NITBNFZKSzVyPUGuNFI3QCEQvF2=	NETvbo1USU6JRWK=
SAS	Mk\xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFnPPYpKSzVyPUGuNFQxQDFizszN	M3\1WHNCVkeHUh?=
EFM-19	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVPJR\|UxRTFwMES4O\|kh\|ryP	MkGzV2FPT0WU
Ca9-22	NHrrWW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXu5SnFmUUN3ME2xMlA2OTB5IN88US=>	NEjxc45USU6JRWK=
NBsusSR	NUXCS\|J6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlfJTWM2OD1zLkC1NVY3KM7:TR?=	NHHp[3dUSU6JRWK=
NB13	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUPhSYVGUUN3ME2xMlA2PTBzIN88US=>	NWj0R5FrW0GQR1XS
SF295	MnTmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFrLSWRKSzVyPUGuNFY3OjRizszN	NX7jfmxPW0GQR1XS
U-2-OS	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWr4UGR2UUN3ME2xMlA4QTFzIN88US=>	NVmxN2liW0GQR1XS
NCI-H526	MoTVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NITPUGRKSzVyPUGuNFgzQTFizszN	M4fYOnNCVkeHUh?=
KMOE-2	M3:0[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUXJR\|UxRTFwMEm0NlIh\|ryP	NIjvb4hUSU6JRWK=
RCM-1	NIPtSIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHfSOVFKSzVyPUGuNVIyODJizszN	NWj3dmVbW0GQR1XS
MC116	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mn7FTWM2OD1zLkGzOlIyKM7:TR?=	Mme2V2FPT0WU
NCI-H1092	Mnr6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUDhSm1WUUN3ME2xMlE2PDB4IN88US=>	MWXTRW5ITVJ?
EW-3	NXG3PVRTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlriTWM2OD1zLkG3NlEzKM7:TR?=	MWPTRW5ITVJ?
HCT-116	M1HTT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIT3OndKSzVyPUGuNVc4PSEQvF2=	NXzVW\|ZbW0GQR1XS
MC-IXC	NFP5dnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIH2RlZKSzVyPUGuNVc5QDFizszN	M4P3[nNCVkeHUh?=
LB1047-RCC	M{O4dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWnPS44yUUN3ME2xMlE5OzF{IN88US=>	MkLPV2FPT0WU
VM-CUB-1	M1\mV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2nhVWlEPTB;MT6xPVExQCEQvF2=	M1;UbXNCVkeHUh?=
NB5	NYHGPWVVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWq4WW9OUUN3ME2xMlE6QDV4IN88US=>	MkH6V2FPT0WU
SKG-IIIa	M3nlUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2\5fGlEPTB;MT6yN\|Q3PCEQvF2=	MYXTRW5ITVJ?
HO-1-N-1	M2D3PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1ez[WlEPTB;MT6yN\|g{PSEQvF2=	MVvTRW5ITVJ?
EFO-27	MlXtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{XpbGlEPTB;MT6yOVA1OyEQvF2=	MUHTRW5ITVJ?
MHH-NB-11	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYTJR\|UxRTFwMkizNlkh\|ryP	MlrVV2FPT0WU
SW620	M1Tt[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3nSR2lEPTB;MT6yPVAyQCEQvF2=	MUHTRW5ITVJ?
MOLT-16	MmrZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MknWTWM2OD1zLkK5O\|k4KM7:TR?=	MV7TRW5ITVJ?
NTERA-S-cl-D1	M4HPeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVLJR\|UxRTFwM{G3OlEh\|ryP	Mk\jV2FPT0WU
VA-ES-BJ	M1nsRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIC5d5hKSzVyPUGuN\|I1PzdizszN	MVPTRW5ITVJ?
HCC1419	NFXCWVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUHleWxnUUN3ME2xMlM1ODJ5IN88US=>	M1zibnNCVkeHUh?=
NCI-H69	NUntVXRTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4rnXGlEPTB;MT6zOFEyOiEQvF2=	M3XQ[3NCVkeHUh?=
DEL	M3HM[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWDJR\|UxRTFwM{WxOlIh\|ryP	NViyXnNXW0GQR1XS
LXF-289	NV\VWGhmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH;pT3JKSzVyPUGuN\|UzPCEQvF2=	NX3jXJFrW0GQR1XS
EW-11	MkjuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUPt[lJrUUN3ME2xMlM3ODJ4IN88US=>	MnWyV2FPT0WU
KP-4	NGjOUWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEnFeWRKSzVyPUGuN\|cxQDVizszN	NYDJ[ZVJW0GQR1XS
NOS-1	NEPyNVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1i1RWlEPTB;MT60NVE6PCEQvF2=	NUG3NY1UW0GQR1XS
SK-NEP-1	NELvd4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXTEZldRUUN3ME2xMlQyPjl\|IN88US=>	MWHTRW5ITVJ?
LAMA-84	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWj2NZhuUUN3ME2xMlQ{QTR3IN88US=>	MUjTRW5ITVJ?
ES5	MoiwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{LHTGlEPTB;MT60OFMh\|ryP	MXfTRW5ITVJ?
HuO9	M1WzN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWnyVo16UUN3ME2xMlQ2OzZ{IN88US=>	Mmm3V2FPT0WU
COLO-684	NHriN29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWnOOVJHUUN3ME2xMlQ3OTF6IN88US=>	M{nzTnNCVkeHUh?=
EW-24	NVnuZ4RRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXq4SZFrUUN3ME2xMlQ3PTNzIN88US=>	Mnv6V2FPT0WU
BV-173	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIDvPJBKSzVyPUGuOFczQTFizszN	NULSSXc{W0GQR1XS
NCI-H1770	MnvZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2nM[2lEPTB;MT60PFU{PiEQvF2=	NFvwTFFUSU6JRWK=
HuP-T4	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVPJR\|UxRTFwNEmzJO69VQ>?	M1\RT3NCVkeHUh?=
TYK-nu	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYDmSW1SUUN3ME2xMlQ6QDVzIN88US=>	MUDTRW5ITVJ?
YH-13	NWDFWFFDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4XuOGlEPTB;MT60PVg6PCEQvF2=	M4fxVXNCVkeHUh?=
H4	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWLj[GZyUUN3ME2xMlUxQTF{IN88US=>	MoWwV2FPT0WU
OVCAR-8	NEH3[I1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnzZTWM2OD1zLkW0OFc4KM7:TR?=	MULTRW5ITVJ?
NCI-H23	M1:5eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnizTWM2OD1zLkW0OlQ2KM7:TR?=	M3PjXXNCVkeHUh?=
ES7	M{fZTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1z6XGlEPTB;MT61OFc4OyEQvF2=	NXfCZm45W0GQR1XS
COR-L88	M{KxNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnTqTWM2OD1zLkW2OFI1KM7:TR?=	NEnQb3hUSU6JRWK=
TI-73	M3vnNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoPCTWM2OD1zLkW5NFYh\|ryP	NHH6bWxUSU6JRWK=
RT-112	Mnu0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4Pm[WlEPTB;MT61PVI5PCEQvF2=	M1j3e3NCVkeHUh?=
HuO-3N1	M{HITWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NH\jeHhKSzVyPUGuOVk{QDVizszN	NIjOcIlUSU6JRWK=
HC-1	NXPFd4NoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGLLcWVKSzVyPUGuOVk5PjZizszN	MUTTRW5ITVJ?
HT55	Mle4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4LRV2lEPTB;MT62OVE{OSEQvF2=	MYfTRW5ITVJ?
IA-LM	M3H5bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVLJR\|UxRTFwNkmyO\|gh\|ryP	Mne4V2FPT0WU
EM-2	NX;pVId2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYrHUY9pUUN3ME2xMlcxODF2IN88US=>	NYTTWHdJW0GQR1XS
MHH-ES-1	MmT6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NI[2VW1KSzVyPUGuO\|A1OzVizszN	NIX2VpRUSU6JRWK=
CAL-27	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NE\uV5RKSzVyPUGuO\|A3OjFizszN	NYTSZ3NwW0GQR1XS
COLO-800	Mlu5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlXVTWM2OD1zLkexNVc6KM7:TR?=	MU\TRW5ITVJ?
HCE-T	MkD2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXjGS5pOUUN3ME2xMlcyPSEQvF2=	MW\TRW5ITVJ?
CAMA-1	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mn2yTWM2OD1zLkexPVcyKM7:TR?=	MlrwV2FPT0WU
LOXIMVI	MknDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoroTWM2OD1zLkeyNVEh\|ryP	NV\mPHFmW0GQR1XS
NH-12	MoHlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NE\WbI9KSzVyPUGuO\|I3QTFizszN	MUjTRW5ITVJ?
TCCSUP	MnPZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnjSTWM2OD1zLkeyPFI6KM7:TR?=	NUTu[lR5W0GQR1XS
MDA-MB-361	MnzNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGTNb5ZKSzVyPUGuO\|MyPTdizszN	NFnofo5USU6JRWK=
EW-16	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NU\h[ZI{UUN3ME2xMlc1OTB5IN88US=>	M2D6cXNCVkeHUh?=
SNU-423	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGXYeFNKSzVyPUGuO\|U5OjdizszN	M3GzO3NCVkeHUh?=
Daoy	NETJR21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MojMTWM2OD1zLke2N\|E6KM7:TR?=	NXO2[npZW0GQR1XS
ES4	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2jweWlEPTB;MT63PFc1OSEQvF2=	NF\zNFNUSU6JRWK=
PFSK-1	NIPwXXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFnHem1KSzVyPUGuPFA{PyEQvF2=	M1vBcnNCVkeHUh?=
ES3	NHrUUGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlntTWM2OD1zLkiyOlgyKM7:TR?=	M3j5Z3NCVkeHUh?=
ONS-76	NHLqcGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4\BXGlEPTB;MT64Nlg6PyEQvF2=	NX7kbJBqW0GQR1XS
JVM-3	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHzVfW9KSzVyPUGuPFU1PTFizszN	MX3TRW5ITVJ?
OS-RC-2	MlXNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnrXTWM2OD1zLki3NVUyKM7:TR?=	NV7MOlk2W0GQR1XS
COLO-320-HSR	MmnYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUe3RnZ4UUN3ME2xMlg5OTl5IN88US=>	NU\yN5NnW0GQR1XS
HN	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mo\lTWM2OD1zLki4O\|I2KM7:TR?=	NELad4tUSU6JRWK=
HT	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVPJR\|UxRTFwOEi5OFch\|ryP	NWToNYM3W0GQR1XS
LoVo	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFXLeJBKSzVyPUGuPFk5OSEQvF2=	NInWRVdUSU6JRWK=
CGTH-W-1	MorXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYHJR\|UxRTFwOEm5OFYh\|ryP	M{fYXHNCVkeHUh?=
NB6	NYLvUohjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkL2TWM2OD1zLkmxNlk5KM7:TR?=	NFvCcZhUSU6JRWK=
EW-22	NVr1VodWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFr1RWhKSzVyPUGuPVI5QDdizszN	MXLTRW5ITVJ?
ES6	NYD2OlhUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmrETWM2OD1zLkmzOlMyKM7:TR?=	NI\6UHZUSU6JRWK=
SCC-15	M3u4bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml\RTWM2OD1zLkmzPFE6KM7:TR?=	MnToV2FPT0WU
HL-60	M3jNRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmfiTWM2OD1zLkmzPVAzKM7:TR?=	NW\NXXRIW0GQR1XS
human HOP-92	NUPqR4lQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NILWSIlKSzVyPUGuPVQxPjVizszN	M4PNfXNCVkeHUh?=
SW626	NF2xNHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXTTbpRJUUN3ME2xMlk1QDl7IN88US=>	M2Dab3NCVkeHUh?=
HEC-1	M3rpUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{TlUGlEPTB;MT65OVM3KM7:TR?=	MnvUV2FPT0WU
LB2241-RCC	NIq5ZW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NX6wZ5NDUUN3ME2xMlk5OjNzIN88US=>	M3q0enNCVkeHUh?=
Ramos-2G6-4C10	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUflXmNzUUN3ME2xMlk6PDl\|IN88US=>	MV7TRW5ITVJ?
A101D	MmfvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWnVTZY4UUN3ME2yMlIxOzB\|IN88US=>	MkjEV2FPT0WU
NCI-H446	NHHSbohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWrJR\|UxRTJwMES1PVkh\|ryP	M4HaPHNCVkeHUh?=
SBC-5	NWLhbpB6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnmwTWM2OD1{LkC2NVQ4KM7:TR?=	MoDVV2FPT0WU
HOS	M3;w[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF30WZBKSzVyPUKuNFc3PTNizszN	NVTCU\|ZpW0GQR1XS
K5	NGLiRnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUfJR\|UxRTJwMEe4NVEh\|ryP	MXjTRW5ITVJ?
HLE	M33WeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVPwVWJ1UUN3ME2yMlA5PTJ7IN88US=>	NW\RN2ROW0GQR1XS
HSC-2	MmjSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkH5TWM2OD1{LkGyPFk5KM7:TR?=	MmHrV2FPT0WU
LCLC-97TM1	NF;GeJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MX7JR\|UxRTJwMUS1PFMh\|ryP	NGHXenZUSU6JRWK=
DMS-273	NVy0[WxUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWfJR\|UxRTJwMUS4N\|ch\|ryP	M3LsNXNCVkeHUh?=
TE-8	NWDie3FFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIHyZ5JKSzVyPUKuNVU4PjVizszN	NGLwVphUSU6JRWK=
DSH1	M1Ppcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWHFUnEyUUN3ME2yMlE3Ozl6IN88US=>	NVi4fVh4W0GQR1XS
CAL-51	MnLPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGHLe5JKSzVyPUKuNVY3QTlizszN	MmrGV2FPT0WU
IST-SL1	NXfsVGlST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFTBV\|RKSzVyPUKuNVY5PDRizszN	MUDTRW5ITVJ?
GCT	NFXNZ45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkPzTWM2OD1{LkG3O\|ch\|ryP	NXnaVXlEW0GQR1XS
SW948	MknzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{\1TGlEPTB;Mj6xPFQ2PiEQvF2=	NIHMXJZUSU6JRWK=
NOMO-1	M{HtVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYX1S4hpUUN3ME2yMlE6OzF5IN88US=>	NVm0d\|JMW0GQR1XS
C8166	MnTrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmjETWM2OD1{LkKxN\|M1KM7:TR?=	NYP6UHpYW0GQR1XS
OC-314	NGO4T4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NG\Ve3VKSzVyPUKuNlMzPTlizszN	MYrTRW5ITVJ?
CAL-39	M1rmOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVvJR\|UxRTJwMkO2NlYh\|ryP	NH;2ZohUSU6JRWK=
MDA-MB-453	NEGxV\|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIrpVGNKSzVyPUKuNlQzPzVizszN	NW\FbI8{W0GQR1XS
A673	NYWxfIlLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYTJR\|UxRTJwMkW4OlIh\|ryP	MVPTRW5ITVJ?
HTC-C3	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWDIVHNtUUN3ME2yMlI3QDVizszN	M1jRWnNCVkeHUh?=
NCI-H1666	NIi2N2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV3w[\|lsUUN3ME2yMlI5OTFzIN88US=>	MmGxV2FPT0WU
PSN1	NX7iU\|I5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFfMVFdKSzVyPUKuNlg6OTNizszN	MWnTRW5ITVJ?
GI-1	NV:2Om0zT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIrrcYtKSzVyPUKuN\|A2PDNizszN	MYnTRW5ITVJ?
HuH-7	NH\NOm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4PGd2lEPTB;Mj6zNFY{PyEQvF2=	NYXO[IdKW0GQR1XS
JAR	M3PybWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVzZOmg3UUN3ME2yMlMyQTh5IN88US=>	NYrpXWNTW0GQR1XS
5637	MoTRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX;JR\|UxRTJwM{KxNlkh\|ryP	Ml\5V2FPT0WU
GB-1	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3fNN2lEPTB;Mj6zNlM{PSEQvF2=	MVPTRW5ITVJ?
KP-N-YS	MmPKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUjJR\|UxRTJwM{K2NVUh\|ryP	MnvvV2FPT0WU
OAW-42	Ml7US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NILlSWRKSzVyPUKuN\|M1OTZizszN	NIPCeHFUSU6JRWK=
8-MG-BA	MoTIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYrJR\|UxRTJwM{O5NFYh\|ryP	MUXTRW5ITVJ?
RH-18	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYPDd48{UUN3ME2yMlM2ODJ{IN88US=>	NVO4UGR3W0GQR1XS
NCI-H1155	NFLNOWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFn4NW5KSzVyPUKuN\|Y4OjVizszN	M{TZcXNCVkeHUh?=
NB17	NFWzZXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXvJR\|UxRTJwM{iyOFMh\|ryP	MoPwV2FPT0WU
NCI-H1437	NWLHSFE1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFH0SphKSzVyPUKuOFE5PzNizszN	M37T[XNCVkeHUh?=
SN12C	NILs[VJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFjqOlBKSzVyPUKuOFMzOTRizszN	M4rjNHNCVkeHUh?=
HSC-3	MlrFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4fufmlEPTB;Mj60OFUxQSEQvF2=	NHe3W2RUSU6JRWK=
GAMG	MnzhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVrJR\|UxRTJwNES1OlEh\|ryP	NF;WfnVUSU6JRWK=
HT-1080	NUXkeoxtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVPN[Vk{UUN3ME2yMlQ1QDZ2IN88US=>	NYrjPXRSW0GQR1XS
A549	NInRT5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkLNTWM2OD1{LkS0PFk{KM7:TR?=	MmOwV2FPT0WU
KNS-62	NXvRTZJqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXjJR\|UxRTJwNEWwOlEh\|ryP	Mnq2V2FPT0WU
YKG-1	NVm5PIZWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFrGb2VKSzVyPUKuOFU1OzdizszN	M1fRcXNCVkeHUh?=
LU-134-A	M3vaUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4PV[mlEPTB;Mj60O\|AxQCEQvF2=	NHnJUJBUSU6JRWK=
FADU	NYHk[\|Z6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVzJR\|UxRTJwNEexOlIh\|ryP	NWT5e5Z5W0GQR1XS
TGBC11TKB	NY\pVWJMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV7JR\|UxRTJwNEexO\|ch\|ryP	NFjvPG5USU6JRWK=
HT-3	NHf5WY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MorHTWM2OD1{LkS5OVM2KM7:TR?=	M3rZTnNCVkeHUh?=
NCI-H2170	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV7MWG5CUUN3ME2yMlUxPTR7IN88US=>	M3fDfXNCVkeHUh?=
Mo-T	MknuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUDJR\|UxRTJwNUC5Nlch\|ryP	MXPTRW5ITVJ?
CCRF-CEM	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2jjcWlEPTB;Mj61N\|A1OyEQvF2=	MnHBV2FPT0WU
KU-19-19	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4rYeGlEPTB;Mj61N\|UyOyEQvF2=	NEWzTYRUSU6JRWK=
NCI-H1048	M3O4RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2mwdmlEPTB;Mj61OVAzPSEQvF2=	MkHVV2FPT0WU
KOSC-2	NUTpXYQ4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NInVV5pKSzVyPUKuOVYxPzZizszN	MorvV2FPT0WU
A431	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXLJR\|UxRTJwNU[zN\|Uh\|ryP	NXz5RZN3W0GQR1XS
COR-L23	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml;ZTWM2OD1{LkW4OVY3KM7:TR?=	M2C1S3NCVkeHUh?=
MKN28	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFrxNHBKSzVyPUKuOVkxOzdizszN	NWLMc3BGW0GQR1XS
22RV1	NHXaTW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{e0fWlEPTB;Mj61PVI4PCEQvF2=	MmrhV2FPT0WU
ABC-1	NFHacplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M334eGlEPTB;Mj62NFQ3KM7:TR?=	NUT2WGlvW0GQR1XS
NCI-H2126	NG\5S4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M120[GlEPTB;Mj62NFk5PCEQvF2=	NUHCdZNKW0GQR1XS
DoTc2-4510	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWX5TYlMUUN3ME2yMlYzOTh3IN88US=>	NXjjWZRDW0GQR1XS
SCC-4	M{nSNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUPJR\|UxRTJwNkOwNVIh\|ryP	NEnFUW9USU6JRWK=
NCI-H661	NYjkRpNmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NITLSZZKSzVyPUKuOlQxQDVizszN	M4G5bnNCVkeHUh?=
RPMI-2650	M1G0cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2n6b2lEPTB;Mj62OFE1OyEQvF2=	NFHrfIxUSU6JRWK=
NCI-H510A	M2HkOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHq3c4VKSzVyPUKuOlQ1OjZizszN	MX7TRW5ITVJ?
BPH-1	MmnqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnvKTWM2OD1{Lk[1PFUh\|ryP	MV3TRW5ITVJ?
M14	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFjkSIVKSzVyPUKuOlY6QTNizszN	M2XMWXNCVkeHUh?=
G-402	NGLyZpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnzuTWM2OD1{LkewOFUyKM7:TR?=	NFfyTYVUSU6JRWK=
AsPC-1	Mn7ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFPNOohKSzVyPUKuO\|EyPyEQvF2=	NXnFenBTW0GQR1XS
NB12	M1\CfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVL3S41lUUN3ME2yMlcyPzFizszN	MnftV2FPT0WU
SK-HEP-1	NIjtNIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHfie25KSzVyPUKuO\|Q{QTFizszN	MmnrV2FPT0WU
U-266	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlThTWM2OD1{Lke3NVIyKM7:TR?=	MYLTRW5ITVJ?
AM-38	M3fPd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1jjTmlEPTB;Mj63O\|M2PSEQvF2=	M2nhWXNCVkeHUh?=
PC-14	NW[1dWdxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NILtdopKSzVyPUKuPFA2OSEQvF2=	NHj2UHFUSU6JRWK=
EGI-1	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1zGOGlEPTB;Mj64NVc1OyEQvF2=	M37zVHNCVkeHUh?=
LS-411N	M1vvWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGjQVnZKSzVyPUKuPFI{OyEQvF2=	NGO0cmNUSU6JRWK=
BFTC-905	MnPwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFrqbIxKSzVyPUKuPFU2OjNizszN	M3TCenNCVkeHUh?=
CaR-1	M3HWeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUHJR\|UxRTJwOE[g{txO	NI\N[mZUSU6JRWK=
NCI-H292	NVm2OYhUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVflO49iUUN3ME2yMlg3PTl4IN88US=>	NX\XfXJmW0GQR1XS
8305C	NHm2cZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXLLRm5YUUN3ME2yMlg3PjR3IN88US=>	NUXIPVBNW0GQR1XS
SNU-449	MnnoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn34TWM2OD1{Lki5NVgzKM7:TR?=	NXz4fnZIW0GQR1XS
LCLC-103H	NXi0VpI3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIWyZXdKSzVyPUKuPVA1OzhizszN	NXrhSYozW0GQR1XS
SW1573	NGPWU5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEnZd45KSzVyPUKuPVYxQDJizszN	NVy4fpdnW0GQR1XS
MLMA	NWrXWFQzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXvJR\|UxRTJwOU[3NVch\|ryP	MnjmV2FPT0WU
NCI-H1355	M{fhemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn:wTWM2OD1\|LkCwO\|k3KM7:TR?=	NFTKdFVUSU6JRWK=
RMG-I	NF64fINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUTDdWo4UUN3ME2zMlAzPTl{IN88US=>	NGHzV4pUSU6JRWK=
BB65-RCC	NVrJdIw1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2rMW2lEPTB;Mz6wN\|MyPCEQvF2=	MYTTRW5ITVJ?
PC-3	M1vROWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIjhfHVKSzVyPUOuNFM5PzRizszN	Mle0V2FPT0WU
SF268	NX7pcWx{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGrEOodKSzVyPUOuNFQ2OjNizszN	M{\BXHNCVkeHUh?=
NCI-H810	Mn:wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnrMTWM2OD1\|LkC0PFI{KM7:TR?=	NIXs[ppUSU6JRWK=
MEG-01	NXvkPXpTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnXHTWM2OD1\|LkC2NVY1KM7:TR?=	M3eyPHNCVkeHUh?=
SW13	NUP6WoRZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NF3YOmVKSzVyPUOuNFc5PDdizszN	NUHLdGJRW0GQR1XS
RH-1	NUPSc4FUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFzBb\|dKSzVyPUOuNVAzPzhizszN	NWe3cZZvW0GQR1XS
GT3TKB	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWewdW9EUUN3ME2zMlEyOjh\|IN88US=>	MWTTRW5ITVJ?
TK10	NInOWVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGrhVHhKSzVyPUOuNVM4OjRizszN	M4jZ[nNCVkeHUh?=
T-24	M{iwb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NI\3RppKSzVyPUOuNVUxPyEQvF2=	MlzQV2FPT0WU
A498	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MULJR\|UxRTNwMkC4O\|Eh\|ryP	NWDaWVV4W0GQR1XS
GR-ST	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoLzTWM2OD1\|LkKyNVM6KM7:TR?=	NITFbnRUSU6JRWK=
LB2518-MEL	M{jUe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M33r[2lEPTB;Mz6yNlM6QCEQvF2=	MlLLV2FPT0WU
T47D	M3roO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2jhRmlEPTB;Mz6yN\|YzPyEQvF2=	NH3kR\|JUSU6JRWK=
NCI-H1651	NF3POmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEWwflFKSzVyPUOuNlQ3PDRizszN	NXzVe3lwW0GQR1XS
EC-GI-10	NG\sO2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHXqW\|BKSzVyPUOuNlYyPTNizszN	MYrTRW5ITVJ?
HT-29	NX6xcIFET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWXJPJlZUUN3ME2zMlI3PjF2IN88US=>	MlrzV2FPT0WU
GI-ME-N	MmnFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M13OR2lEPTB;Mz6yPVUyOSEQvF2=	MYDTRW5ITVJ?
SW756	MoPUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVHJR\|UxRTNwMkm2Nlkh\|ryP	M13mOnNCVkeHUh?=
RKO	MlLkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4jW[WlEPTB;Mz6zNFc2PyEQvF2=	MVLTRW5ITVJ?
NCI-H1563	MlHFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEnGW\|hKSzVyPUOuN\|MxOThizszN	NVPOS3U1W0GQR1XS
DJM-1	MnnNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIDHTnpKSzVyPUOuN\|c3PzRizszN	NEjOPGxUSU6JRWK=
L-428	M{nsXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1zwcWlEPTB;Mz60NFA1PSEQvF2=	MlfDV2FPT0WU
NCI-H2122	NV[wcnBbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWPJR\|UxRTNwNEGzNVIh\|ryP	MU\TRW5ITVJ?
Ca-Ski	NGPCN\|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXzmRYI{UUN3ME2zMlQ2PDNizszN	MULTRW5ITVJ?
639-V	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3mxNWlEPTB;Mz60OlA2PyEQvF2=	MVnTRW5ITVJ?
SW1116	MlztS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnrNTWM2OD1\|LkS2NlY6KM7:TR?=	NW\oOWo1W0GQR1XS
DMS-114	M{fnd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmPzTWM2OD1\|LkS3NFY3KM7:TR?=	NXPq[5B6W0GQR1XS
MZ2-MEL	M1X0b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGGxdoJKSzVyPUOuOFc3QDFizszN	NXzXNpU6W0GQR1XS
COLO-829	M1fjZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoXpTWM2OD1\|LkWwNFc{KM7:TR?=	MVXTRW5ITVJ?
J82	MojCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3PkdGlEPTB;Mz61NFU4KM7:TR?=	NVnpbXFqW0GQR1XS
EW-13	NWL5cI5mT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4\mVmlEPTB;Mz61NlUyKM7:TR?=	M3j6XXNCVkeHUh?=
RXF393	NYfGbZdmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXrpXJNoUUN3ME2zMlU{Ojl2IN88US=>	MUXTRW5ITVJ?
CAL-62	M3rWN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkLvTWM2OD1\|LkW0OVE1KM7:TR?=	Mnv3V2FPT0WU
OCUB-M	NISxc3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUTOc3BrUUN3ME2zMlU1PjZ3IN88US=>	MnrmV2FPT0WU
BT-474	NUX2bWV5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2GwO2lEPTB;Mz62N\|MyKM7:TR?=	MYTTRW5ITVJ?
KYSE-180	M2rPcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2PsT2lEPTB;Mz62N\|M4OiEQvF2=	MWXTRW5ITVJ?
NCI-H650	NWP3bHpFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX3JR\|UxRTNwNkSyPFch\|ryP	NFjKfYdUSU6JRWK=
Detroit562	M{XtV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIPB[HNKSzVyPUOuOlUxOjJizszN	M{TPeXNCVkeHUh?=
SW48	NGLUUYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1j1bmlEPTB;Mz62OVY2PyEQvF2=	MXPTRW5ITVJ?
KYSE-450	MkjIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MljqTWM2OD1\|Lk[4OVgzKM7:TR?=	MnPKV2FPT0WU
KYSE-510	M3LOXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoqzTWM2OD1\|LkeyNVgyKM7:TR?=	MmfRV2FPT0WU
GP5d	NFzxdndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoXDTWM2OD1\|LkeyPVUh\|ryP	M{nZUnNCVkeHUh?=
RPMI-7951	M3ixcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX22RlFwUUN3ME2zMlc1PzJ\|IN88US=>	M1\Fe3NCVkeHUh?=
Becker	NVjHXogyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFfidJlKSzVyPUOuO\|UxOTJizszN	MlvKV2FPT0WU
WM-115	NHnFemlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUHJR\|UxRTNwN{ixPVUh\|ryP	NUDMUVBrW0GQR1XS
G-401	M3PGVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXzJR\|UxRTNwN{mwPFUh\|ryP	NYDDcldsW0GQR1XS
PANC-08-13	M1;ldmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHvLfJhKSzVyPUOuO\|k3ODJizszN	M4joNnNCVkeHUh?=
SW982	NXrj[\|ZDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHG1XpNKSzVyPUOuPFA2PTFizszN	M1zFNHNCVkeHUh?=
D-263MG	NILzWmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkHJTWM2OD1\|LkiyNFUyKM7:TR?=	M3qy[3NCVkeHUh?=
KM-H2	M{HvUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVLJR\|UxRTNwOEK2NlQh\|ryP	MWnTRW5ITVJ?
SK-MEL-3	NITJUolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnvZTWM2OD1\|LkiyPFQyKM7:TR?=	MlrKV2FPT0WU
NCI-H1581	NUf2XFg1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVPJR\|UxRTNwOES0PFgh\|ryP	NVnoVI45W0GQR1XS
LS-123	NX\KSZoxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnjCTWM2OD1\|Lki3PVA6KM7:TR?=	M37reXNCVkeHUh?=
CAKI-1	M3jyVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWPJR\|UxRTNwOEmwOVIh\|ryP	MkPXV2FPT0WU
MEL-JUSO	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFG2VmdKSzVyPUOuPFkyPTNizszN	MVfTRW5ITVJ?
HCE-4	NYrY[GQ2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NF\GXVNKSzVyPUOuPVE3PjNizszN	NXXtO\|hZW0GQR1XS
TE-10	MlzPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWfJR\|UxRTNwOUKwNUDPxE1?	MYLTRW5ITVJ?
OVCAR-4	MmnDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXfJR\|UxRTNwOUK4PFkh\|ryP	MUjTRW5ITVJ?
ETK-1	NWfxW3k3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHO4TWNKSzVyPUOuPVQ3OzVizszN	M2DX[XNCVkeHUh?=
A2780	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MojZTWM2OD12LkC1PVY3KM7:TR?=	Mn7RV2FPT0WU
LU-65	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGWwWYpKSzVyPUSuNFc3OzNizszN	NH20fZFUSU6JRWK=
BHY	Mnf6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHTjV5FKSzVyPUSuNVI1QTVizszN	MXjTRW5ITVJ?
COR-L105	M3m4[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVn2O5V{UUN3ME20MlE{ODVzIN88US=>	MXvTRW5ITVJ?
CAL-12T	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlvLTWM2OD12LkGzNVA{KM7:TR?=	MYrTRW5ITVJ?
SCH	NEC4fJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlrqTWM2OD12LkG1O\|Q{KM7:TR?=	NYW2VG5OW0GQR1XS
CW-2	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUXJR\|UxRTRwMUmwNFEh\|ryP	M1raW3NCVkeHUh?=
HCC1806	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFi1Z2dKSzVyPUSuNlA{OTJizszN	NWixTJR[W0GQR1XS
KP-N-YN	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml[zTWM2OD12LkKwPVI4KM7:TR?=	NHf4XmRUSU6JRWK=
T98G	M3;ReWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWTBb2pSUUN3ME20MlIzOTV5IN88US=>	NGf2NYZUSU6JRWK=
CAL-54	NVvMdI9[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2jJb2lEPTB;ND6yNlM5OSEQvF2=	NH7MU4RUSU6JRWK=
CAL-33	MlvFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFnnfJhKSzVyPUSuNlMxPjRizszN	NGjCUnlUSU6JRWK=
SNU-C2B	MnPqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NETGWZdKSzVyPUSuNlQ4PjlizszN	M4fpOnNCVkeHUh?=
NUGC-3	M4D2S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX7JR\|UxRTRwMkW1NFUh\|ryP	NWXYU3A{W0GQR1XS
DOK	MoS2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUDJR\|UxRTRwMk[1PVMh\|ryP	Mlr2V2FPT0WU
MMAC-SF	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH\xeolKSzVyPUSuNlY5PTlizszN	NFToenJUSU6JRWK=
KYSE-70	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M37mNGlEPTB;ND6yPVM1KM7:TR?=	MVHTRW5ITVJ?
A204	NFzUZZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mm[4TWM2OD12LkO1PFA{KM7:TR?=	NXzUeG8{W0GQR1XS
SCC-25	Ml\HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX7oRphMUUN3ME20MlM2QDF7IN88US=>	MY\TRW5ITVJ?
EPLC-272H	NETSR3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVHJR\|UxRTRwM{i5OUDPxE1?	Mk\IV2FPT0WU
CAL-120	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIPmXHJKSzVyPUSuN\|g6QTJizszN	MVLTRW5ITVJ?
LS-513	NV3mbXo3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoDvTWM2OD12LkSyNVk5KM7:TR?=	MYDTRW5ITVJ?
CAPAN-1	NFn0XmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2LjU2lEPTB;ND60NlM5OiEQvF2=	Ml6zV2FPT0WU
ESS-1	NXnlNm05T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmfUTWM2OD12LkSyO\|I1KM7:TR?=	Mn3WV2FPT0WU
GMS-10	NUTlWIVmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFTUSpRKSzVyPUSuOFI5OTlizszN	MXLTRW5ITVJ?
NCI-N87	NFPzO45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH3QSGdKSzVyPUSuOVA5PjhizszN	MUXTRW5ITVJ?
HMV-II	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWexNlM5UUN3ME20MlUyPzNizszN	NGLYPYhUSU6JRWK=
COLO-741	NWTzW402T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnrETWM2OD12LkW1PVk1KM7:TR?=	M2HicHNCVkeHUh?=
MKN45	NH;zc\|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYf4Nm9wUUN3ME20MlU4PzN{IN88US=>	M3fTOXNCVkeHUh?=
OAW-28	NFOxdpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkjsTWM2OD12LkW4N\|k5KM7:TR?=	NVvaO4E1W0GQR1XS
OCI-AML2	NWL0XXUzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWDJR\|UxRTRwNkWyN\|gh\|ryP	NIPjOmVUSU6JRWK=
MDA-MB-231	M{X6Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGTv[VVKSzVyPUSuO\|AzPDNizszN	M3z1WHNCVkeHUh?=
NCI-H1648	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUDJR\|UxRTRwN{KyO\|Mh\|ryP	NGezPXdUSU6JRWK=
NCI-H1792	MlnSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{LuS2lEPTB;ND63OlExPyEQvF2=	MUPTRW5ITVJ?
GCIY	NGfvNVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{DtPWlEPTB;ND63O\|QzPCEQvF2=	NH36PGhUSU6JRWK=
Hs-578-T	MmLCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MY\JR\|UxRTRwN{e2OVUh\|ryP	MYPTRW5ITVJ?
SW962	MkfXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF\DU4NKSzVyPUSuO\|gxOTFizszN	M1jKRnNCVkeHUh?=
NCI-H630	NEPFfmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWnJR\|UxRTRwN{iwPFEh\|ryP	NXHpXnI2W0GQR1XS
786-0	MnrsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUPzW5l{UUN3ME20Mlc5Pzd\|IN88US=>	MnLXV2FPT0WU
FTC-133	M3j4UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWLSPJhbUUN3ME20Mlc6OjZ\|IN88US=>	M3[5T3NCVkeHUh?=
BT-20	Mlu3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NU\vfINHUUN3ME20Mlc6PDJ7IN88US=>	MXLTRW5ITVJ?
Mewo	NEfDPVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWLJR\|UxRTRwOEG3OFch\|ryP	M3vSVnNCVkeHUh?=
SW780	M3m2TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmnGTWM2OD12Lki1O\|Y3KM7:TR?=	NEDO[VFUSU6JRWK=
OE33	M{P2d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml3vTWM2OD12Lki3O\|E{KM7:TR?=	NVO1cW5VW0GQR1XS
HCC1569	NWXieINJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmGyTWM2OD12Lki4OFU5KM7:TR?=	NXvscI82W0GQR1XS
TE-6	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEX3e3lKSzVyPUSuPVM6PzdizszN	MluyV2FPT0WU
SK-N-FI	M1TUfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXvJR\|UxRTRwOUS0NlEh\|ryP	NVTKO5JUW0GQR1XS
PANC-03-27	NFL3NJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlzCTWM2OD12Lkm5PVYzKM7:TR?=	MlT0V2FPT0WU
MCF7	NFP5RnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmmwTWM2OD13LkCwO\|M5KM7:TR?=	NXzjUHJOW0GQR1XS
UACC-257	Mo\yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGnFNlZKSzVyPUWuNFI5PDVizszN	MYnTRW5ITVJ?
SW1088	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUfJR\|UxRTVwMEK5OFQh\|ryP	NID5TnVUSU6JRWK=
A704	M{jVbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXjwSoZWUUN3ME21MlA{ODZizszN	MoW5V2FPT0WU
A2058	NVzu[VhHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVnURYsxUUN3ME21MlA2QTB6IN88US=>	MXHTRW5ITVJ?
Calu-3	NVTsUWkyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVfJR\|UxRTVwME[0OVIh\|ryP	M{nLbnNCVkeHUh?=
RERF-LC-MS	NYeyN\|hUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVy2fIFWUUN3ME21MlA3QTB\|IN88US=>	MorUV2FPT0WU
AU565	M2XQbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXHJR\|UxRTVwMEm3NFIh\|ryP	NUPGbY1yW0GQR1XS
DMS-79	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnrJTWM2OD13LkGzPFg{KM7:TR?=	NWPBR4w3W0GQR1XS
DK-MG	M3uwPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXTJSnF4UUN3ME21MlE5PDN6IN88US=>	NHLBc5VUSU6JRWK=
HuCCT1	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4jYNGlEPTB;NT6yN\|g2PiEQvF2=	NWDNVlZ6W0GQR1XS
HT-144	M3zPUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MV\JR\|UxRTVwMkS5PFch\|ryP	NIS0d2VUSU6JRWK=
M059J	NHPXZ3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmH6TWM2OD13LkK1O\|Yh\|ryP	MXfTRW5ITVJ?
COLO-792	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX\JR\|UxRTVwMk[zOVYh\|ryP	MVTTRW5ITVJ?
SF539	MnvaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVTJR\|UxRTVwMk[2N\|Ih\|ryP	NIj6Z2tUSU6JRWK=
SK-UT-1	M3zkPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYO0ZXB2UUN3ME21MlI4PzVzIN88US=>	Ml7vV2FPT0WU
NCI-H1703	NHL0PXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYnu[YdUUUN3ME21MlM2QDJ4IN88US=>	M2C2cHNCVkeHUh?=
SW837	NVHEfHI4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1LOZ2lEPTB;NT6zO\|g4QCEQvF2=	M1nBTHNCVkeHUh?=
U251	MmLYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUPJR\|UxRTVwM{mwPVYh\|ryP	NHnWcnBUSU6JRWK=
SW1710	NETXPGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NX7QU3JXUUN3ME21MlQyPTV2IN88US=>	Mn;0V2FPT0WU
NCI-H1299	MnzPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlLZTWM2OD13LkS2N\|M2KM7:TR?=	MU\TRW5ITVJ?
RVH-421	M2[4U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mne1TWM2OD13LkS5PVA5KM7:TR?=	NWn0RmYyW0GQR1XS
UM-UC-3	NX3MbGtpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3GxV2lEPTB;NT62NlY2OSEQvF2=	NH3MUo5USU6JRWK=
MDA-MB-175-VII	NWniUIRWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGjteotKSzVyPUWuOlQxPDFizszN	M{\xSHNCVkeHUh?=
KYSE-270	NWXEbmJwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFrX[oxKSzVyPUWuOlYxOzFizszN	NWWw[\|k3W0GQR1XS
COLO-668	NEXhclhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUHWOmZkUUN3ME21MlcyOzJizszN	MXrTRW5ITVJ?
LN-405	NIj3UI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXjJR\|UxRTVwN{OwPFUh\|ryP	MVLTRW5ITVJ?
HT-1376	M{[2bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{O2OmlEPTB;NT63PFA2OiEQvF2=	M1jP[3NCVkeHUh?=
769-P	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mm\WTWM2OD13Lki2O\|E5KM7:TR?=	NFPEZYRUSU6JRWK=
HuP-T3	M3rmfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYnJR\|UxRTVwOEi2O\|ch\|ryP	NEPTS3FUSU6JRWK=
MDA-MB-415	MmL5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVvpd\|FtUUN3ME21MlkzOTN7IN88US=>	NYjyb3g5W0GQR1XS
MKN7	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXHJR\|UxRTVwOUi4JO69VQ>?	M2HHUXNCVkeHUh?=
KS-1	NES0[olIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIXNXYpKSzVyPUWuPVg5OzZizszN	M1vPdnNCVkeHUh?=
647-V	M3PYcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXjJR\|UxRTVwOUmxOFgh\|ryP	NHfHNo1USU6JRWK=
COLO-679	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVvXWJduUUN3ME22MlAxOjV3IN88US=>	MXLTRW5ITVJ?
AN3-CA	MoXxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGe2U5dKSzVyPU[uNFM1PDFizszN	M2LSZXNCVkeHUh?=
C32	NVvoPFFPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NW\zSFhSUUN3ME22MlE{ODN2IN88US=>	M2HxWHNCVkeHUh?=
KM12	NFT5RlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF\1eWVKSzVyPU[uNlQxQTlizszN	Ml2yV2FPT0WU
KINGS-1	NUfS[pQzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV7JR\|UxRTZwMk[xOVIh\|ryP	NGDZNFRUSU6JRWK=
KYSE-410	NXjPOFdOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUDJR\|UxRTZwM{C2OFUh\|ryP	NHnxc3ZUSU6JRWK=
HPAF-II	NIHNZVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGDYcW1KSzVyPU[uN\|U1QCEQvF2=	MnTjV2FPT0WU
LAN-6	MoPkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlX4TWM2OD14LkS5OlMyKM7:TR?=	M1LSVHNCVkeHUh?=
LU-99A	NFLiNZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3\6cmlEPTB;Nj61OVk5QSEQvF2=	M4XvUXNCVkeHUh?=
SJSA-1	MlT0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYjJR\|UxRTZwNU[zOFch\|ryP	MWrTRW5ITVJ?
MSTO-211H	NWfGVG83T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2nq[2lEPTB;Nj63NlI{OyEQvF2=	MlS1V2FPT0WU
SW900	NVjzSoVjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGW4[mZKSzVyPU[uO\|YzOjFizszN	MoXjV2FPT0WU
LNCaP-Clone-FGC	MlrmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoHHTWM2OD14LkiwOFA{KM7:TR?=	NYXFcGFkW0GQR1XS
OMC-1	NV\XWJlUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVPJR\|UxRTZwOEW0NFIh\|ryP	MnnHV2FPT0WU
IST-MEL1	M4P5S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1zmXGlEPTB;Nj64PVY3QSEQvF2=	MWLTRW5ITVJ?
TE-9	NVLVUlBHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1v4RWlEPTB;Nj64PVg1PyEQvF2=	NUTYc\|hEW0GQR1XS
NCI-H2030	M1G3WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkL2TWM2OD14LkmxNlI3KM7:TR?=	MUTTRW5ITVJ?
BFTC-909	MlLES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mlz4TWM2OD15LkCwOlQyKM7:TR?=	NGfhbHBUSU6JRWK=
NCI-SNU-5	NYHvVnhkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2e0UGlEPTB;Nz6wNlE2QSEQvF2=	MoLqV2FPT0WU
TE-5	NIHCO4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYDXeYU6UUN3ME23MlAzQDhzIN88US=>	MX;TRW5ITVJ?
SK-MES-1	NUW4O45HT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnzMTWM2OD15LkC1OFI4KM7:TR?=	NGHvXFhUSU6JRWK=
SHP-77	M4XqbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NITRXnlKSzVyPUeuNVM6PTJizszN	M{TSVnNCVkeHUh?=
NCI-H1623	NWjWSWFPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUHJR\|UxRTdwMUSwO\|Ih\|ryP	Mn\mV2FPT0WU
TE-11	NWDERWlpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3z0XGlEPTB;Nz6xOVE5PCEQvF2=	M1jUNXNCVkeHUh?=
EKVX	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml62TWM2OD15LkG5NlY4KM7:TR?=	M1PUWXNCVkeHUh?=
OVCAR-3	Mn:2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4[0dGlEPTB;Nz6yNVE{OyEQvF2=	M4Xjc3NCVkeHUh?=
C3A	NGXkWVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHraWGVKSzVyPUeuN\|Q2OiEQvF2=	NETRSpZUSU6JRWK=
CFPAC-1	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGnmfWNKSzVyPUeuN\|YzOjJizszN	NVrlS3VmW0GQR1XS
MG-63	NXfQSGVjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2mwbGlEPTB;Nz60NVg1QSEQvF2=	MXjTRW5ITVJ?
KYSE-140	NUnJd3VRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYLJR\|UxRTdwNESwOlEh\|ryP	MXrTRW5ITVJ?
MPP-89	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFrWeFVKSzVyPUeuOVk4OjlizszN	NUj1XnBjW0GQR1XS
COLO-824	NEHWeGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV3WSG45UUN3ME23MlczQDZ\|IN88US=>	MVvTRW5ITVJ?
SiHa	M4S5bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVvC[JRIUUN3ME23Mlg{PzB5IN88US=>	NWHiV2t[W0GQR1XS
SNU-387	M2PnV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXf5XnZpUUN3ME23Mlg2OzR5IN88US=>	M2DLbXNCVkeHUh?=
A172	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NInmXYFKSzVyPUeuPFYyPzJizszN	NISySZdUSU6JRWK=
COLO-680N	MnzmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2LVcmlEPTB;Nz65NVc{KM7:TR?=	M13vUXNCVkeHUh?=
HCC1395	M{X2cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MW\JR\|UxRThwMEW0OVIh\|ryP	MUfTRW5ITVJ?
NCI-H28	M1K2fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYPJR\|UxRThwMEW5OlMh\|ryP	MVPTRW5ITVJ?
LC-2-ad	NHG0cHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4TPT2lEPTB;OD6yNVk{PyEQvF2=	MVfTRW5ITVJ?
S-117	NI\GT5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWLJR\|UxRThwMkWzOVMh\|ryP	NVvOfGxZW0GQR1XS
NCI-H1838	MlXDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXv6[lQ5UUN3ME24MlI2PzhzIN88US=>	M4nX[3NCVkeHUh?=
PANC-10-05	NFyyVJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXr3PZRtUUN3ME24MlM4ODR5IN88US=>	MojOV2FPT0WU
KALS-1	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUC1SGJvUUN3ME24MlUxQTJ6IN88US=>	NVLxTXdtW0GQR1XS
LS-1034	NYTTU286T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGTVN2ZKSzVyPUiuOVc1OzdizszN	MVHTRW5ITVJ?
TGBC1TKB	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVnJR\|UxRThwN{O1N\|Uh\|ryP	M1jEWXNCVkeHUh?=
OE19	MkXOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnTwTWM2OD16Lke2NlYzKM7:TR?=	MX3TRW5ITVJ?
D-502MG	MkfCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFW5TYpKSzVyPUiuO\|Y6QTRizszN	MXrTRW5ITVJ?
JEG-3	NGnRNppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1P6NGlEPTB;OD63PFYyQCEQvF2=	NGDSRnlUSU6JRWK=
DBTRG-05MG	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWfsZoF2UUN3ME24Mlg4PTZ3IN88US=>	NGi3OIpUSU6JRWK=
ME-180	NUDsSpN4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoHaTWM2OD17LkC2O\|I2KM7:TR?=	NILodYJUSU6JRWK=
NCI-H1573	MoK4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVnJR\|UxRTlwMUC1N\|Ih\|ryP	MkjoV2FPT0WU
HCC2998	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHnrOJVKSzVyPUmuNVM3QDFizszN	M4rZcnNCVkeHUh?=
ACHN	NGLTd2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIiwZ29KSzVyPUmuNlQ6PzVizszN	NITIdo5USU6JRWK=
D-392MG	MkD5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYnJR\|UxRTlwMkW3NVUh\|ryP	M3r2WHNCVkeHUh?=
no-11	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4fYWWlEPTB;OT6yOlAzQCEQvF2=	M2L3SXNCVkeHUh?=
KLE	NE\ncm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Ml\KTWM2OD17LkOyNlMzKM7:TR?=	MXXTRW5ITVJ?
Calu-6	NH;mcXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MX7JR\|UxRTlwM{e1Nlgh\|ryP	M{XuenNCVkeHUh?=
LB831-BLC	NULqfXQ{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlHDTWM2OD17LkS1NVcyKM7:TR?=	NVzZd4k4W0GQR1XS
SW684	M1rnSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{HYTWlEPTB;OT60OlEyPiEQvF2=	M4TYbHNCVkeHUh?=
SH-4	NUThR\|V2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHnjZnpKSzVyPUmuOFk{PjRizszN	MVzTRW5ITVJ?
IST-MES1	NWjhRXFMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFnXeJBKSzVyPUmuOVE3PDRizszN	NFrteVFUSU6JRWK=
Saos-2	M3PDNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnfxTWM2OD17LkWyNVk2KM7:TR?=	MVPTRW5ITVJ?
NCI-H2087	NFnpNW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXjJR\|UxRTlwNkezOVIh\|ryP	MVvTRW5ITVJ?
SCC-9	NGj3PHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1jyRWlEPTB;OT63NVgyPiEQvF2=	Ml36V2FPT0WU
MFE-280	Moe3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVjJR\|UxRTlwN{K3PFUh\|ryP	NH3iRY1USU6JRWK=
BEN	NU\BRWhwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4nUNGlEPTB;OT64NlE2QSEQvF2=	M1XCOnNCVkeHUh?=
CP50-MEL-B	MoK1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlL0TWM2OD17LkmyOFMzKM7:TR?=	MW\TRW5ITVJ?
SK-MEL-28	NV3lNFNZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV;ZO5N1UUN3ME2xNE4xOTl\|IN88US=>	M4TEeHNCVkeHUh?=
NCI-H2452	Ml61S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mly0TWM2OD1zMD6xOkDPxE1?	NXPGdHF3W0GQR1XS
NCI-H1395	NXjVbVltT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn\JTWM2OD1zMD6xO\|gh\|ryP	M1;1OHNCVkeHUh?=
NCI-H2052	NHPHXVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWnJR\|UxRTFyLkG4PFIh\|ryP	MXjTRW5ITVJ?
A375	NYjRSG1rT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFnsNoJKSzVyPUGwMlI1PTJizszN	MVLTRW5ITVJ?
HCC38	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYPJR\|UxRTFyLkOyNkDPxE1?	MnryV2FPT0WU
LK-2	MmrpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVPlXYhjUUN3ME2xNE41OjB6IN88US=>	M{TRWHNCVkeHUh?=
SF126	NWjvd5RmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWLJR\|UxRTFyLkS3Nlch\|ryP	MWPTRW5ITVJ?
SK-MEL-1	NEG2e5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHL3U5hKSzVyPUGwMlc5OzhizszN	NYfNdJB3W0GQR1XS
ACN	MlzrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUH4T\|g3UUN3ME2xNE45Pjd7IN88US=>	NGi4c\|RUSU6JRWK=
BB30-HNC	NXr6fpdST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYTJR\|UxRTFyLki3NVEh\|ryP	MVrTRW5ITVJ?
NCI-H747	M4TnO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX\3bItDUUN3ME2xNE45PzR4IN88US=>	MW\TRW5ITVJ?
KYSE-150	MlnNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXnMbJhTUUN3ME2xNU4xOzh5IN88US=>	M1vTeXNCVkeHUh?=
D-247MG	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2i5fWlEPTB;MUGuNVAxQSEQvF2=	NULqSJRjW0GQR1XS
BxPC-3	NGTwNlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF71eGJKSzVyPUGxMlM4PDdizszN	MXHTRW5ITVJ?
SK-MEL-30	MlnqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4DKcWlEPTB;MUGuOFA4QSEQvF2=	MmDoV2FPT0WU
CAS-1	M{XRfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3P5SGlEPTB;MUGuOFExQSEQvF2=	NIXhVHNUSU6JRWK=
no-10	NHLvenJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYTJR\|UxRTF{LkGyNVch\|ryP	MYnTRW5ITVJ?
NCI-H2405	NXLwbG5vT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUC4UWhFUUN3ME2xNk4zODN4IN88US=>	NG\i[XpUSU6JRWK=
KGN	NGfBUYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{X6NGlEPTB;MUKuNlkxOSEQvF2=	NVWzToRsW0GQR1XS
BB49-HNC	Mmr4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWTrT3ZLUUN3ME2xNk4{QTV4IN88US=>	MXvTRW5ITVJ?
NCI-H1693	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXXJR\|UxRTF{LkW4NVYh\|ryP	MXvTRW5ITVJ?
RO82-W-1	NVH2OZFXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGm1XVRKSzVyPUGzMlA3PDlizszN	NE\VcGxUSU6JRWK=
CAL-85-1	Ml;KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXfJR\|UxRTF\|LkSzPVkh\|ryP	NUL6TpFmW0GQR1XS
H-EMC-SS	M4Psemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXXJR\|UxRTF\|LkmxNFQh\|ryP	NY\UZnVRW0GQR1XS
SW1783	NF3TR5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXfwU4RjUUN3ME2xOE4zOzlzIN88US=>	NEKySVRUSU6JRWK=
LB771-HNC	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mm\aTWM2OD1zND60NVkh\|ryP	MnPZV2FPT0WU
HCC70	NIjvTVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVfwTWs3UUN3ME2xOE41OjN\|IN88US=>	Mor2V2FPT0WU
KNS-81-FD	NVvEc2g5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3fNZmlEPTB;MUSuO\|A1PSEQvF2=	Mn;QV2FPT0WU
KYSE-520	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1XxbGlEPTB;MUSuPVI4KM7:TR?=	NVjKN4JjW0GQR1XS
TGBC24TKB	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWS2UYs{UUN3ME2xOE46PTN7IN88US=>	M330dnNCVkeHUh?=
SNB75	NY\z[GRJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYjwPJc{UUN3ME2xOU4xPzJ7IN88US=>	MmLkV2FPT0WU
SW872	M2fyRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M37qe2lEPTB;MUWuNlIyQCEQvF2=	NEH1NpJUSU6JRWK=
U031	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mly3TWM2OD1zNT64NFI5KM7:TR?=	MVXTRW5ITVJ?
ChaGo-K-1	NHmzdZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUDJR\|UxRTF3LkizOVkh\|ryP	MoDyV2FPT0WU
NCI-H441	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmPETWM2OD1zNj6wNFM6KM7:TR?=	M4ixVnNCVkeHUh?=
TE-12	Mn2xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVi0Z4I3UUN3ME2xOk4yQDd\|IN88US=>	M4LyXXNCVkeHUh?=
NCI-H1755	NHe2XlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV\EWWw1UUN3ME2xOk42PzNizszN	M{\1enNCVkeHUh?=
KNS-42	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmmxTWM2OD1zNj62OVg6KM7:TR?=	NX\LVIhXW0GQR1XS
SK-PN-DW	MmXwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVLJR\|UxRTF5LkSyNFEh\|ryP	Ml3tV2FPT0WU
NCI-H226	M3TmVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIrkfoJKSzVyPUG3Mlk{PDVizszN	NFTIXY5USU6JRWK=
K-562	MnzXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUDJR\|UxRTF6Lk[zNVch\|ryP	NITidVJUSU6JRWK=
A388	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUjJR\|UxRTF7LkCzNFMh\|ryP	Mn;SV2FPT0WU
ZR-75-30	M3fGUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXfW[VVnUUN3ME2xPU4xQTZ6IN88US=>	M1XwU3NCVkeHUh?=
LU-135	NFziPHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4TjWmlEPTB;MUmuNlY{PiEQvF2=	MmnXV2FPT0WU
NCI-H2029	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWjJR\|UxRTF7Lk[wNlEh\|ryP	Ml\EV2FPT0WU
HT-1197	M3HrZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWriXpVrUUN3ME2xPU46OjJ5IN88US=>	MY\TRW5ITVJ?
IGR-1	M37xbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnLPTWM2OD1{MD6zNVE4KM7:TR?=	NGPET3RUSU6JRWK=
U-87-MG	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlK5TWM2OD1{MD62OFE{KM7:TR?=	M3jrdnNCVkeHUh?=
NCI-H1304	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUO5V2JvUUN3ME2yNE44PTBzIN88US=>	MVzTRW5ITVJ?
RCC10RGB	M4LMb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYjJR\|UxRTJzLkK4Nlkh\|ryP	NV;KOINxW0GQR1XS
NCI-H520	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGj0W\|BKSzVyPUKyMlc3OTFizszN	NV7SdGpuW0GQR1XS
SK-LU-1	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NX7pW3U5UUN3ME2yN{4xPzF6IN88US=>	M3XsR3NCVkeHUh?=
UACC-893	NULSTHlWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXfJR\|UxRTJ\|LkGwN\|gh\|ryP	NVHpdFh[W0GQR1XS
NCI-H2347	Mnm2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mli2TWM2OD1{Mz6yOlc1KM7:TR?=	MlTxV2FPT0WU
U-118-MG	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1;4OGlEPTB;MkOuO\|IyPyEQvF2=	Ml;xV2FPT0WU
NCI-H596	M3PTc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{LLRWlEPTB;MkOuPVA2PSEQvF2=	MXXTRW5ITVJ?
MZ1-PC	NHXid\|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mk[5TWM2OD1{ND62O\|U6KM7:TR?=	M2myO3NCVkeHUh?=
SW1417	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWHJR\|UxRTJ3LkK0PVgh\|ryP	MoGyV2FPT0WU
NCI-H82	M4DlfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{HzcWlEPTB;Mk[uOFI5QCEQvF2=	M4DmOXNCVkeHUh?=
COLO-678	NVixWGt4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnviTWM2OD1{Nz60PVE6KM7:TR?=	NYm0NnJYW0GQR1XS
KURAMOCHI	MlfJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYHnNHZkUUN3ME2yPE4yOjZizszN	MmL6V2FPT0WU
NCI-H1650	M4LQW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4PqOGlEPTB;M{CuNVkzPCEQvF2=	NVjENo5LW0GQR1XS
HCC1954	Mm\4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVrUN2MyUUN3ME2zNU4{PjZ4IN88US=>	NYfYXYk4W0GQR1XS
GAK	NWHiWG9WT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX7JR\|UxRTN{LkK2NVYh\|ryP	M2HTcnNCVkeHUh?=
YAPC	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGrVeHFKSzVyPUOzMlc3PDhizszN	NEO1Sm5USU6JRWK=
NCI-H2228	NITWS3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4HzemlEPTB;M{SuN\|YxPSEQvF2=	MX;TRW5ITVJ?
VMRC-RCZ	M3HqbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX3JR\|UxRTN4LkOwNlIh\|ryP	M2nLdHNCVkeHUh?=
NMC-G1	NULQSHBsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NF;tbXpKSzVyPUO3MlA2OjlizszN	Mn7CV2FPT0WU
D-336MG	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHPJRmdKSzVyPUSxMlg1PDJizszN	NGrIUY9USU6JRWK=
UACC-62	NUPzWFg3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlH6TWM2OD12Mj61OVA2KM7:TR?=	M1XD[XNCVkeHUh?=
C-33-A	NEL6UndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmPCTWM2OD12NT6zNlU3KM7:TR?=	NGTMR\|dUSU6JRWK=
HCC1937	MljUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYKxU4VLUUN3ME20O{4yQTV6IN88US=>	MWrTRW5ITVJ?
HDLM-2	M2\QUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1;ZemlEPTB;NEeuNlI5PyEQvF2=	NGm4e5FUSU6JRWK=
NCI-H727	MoTBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MW\JR\|UxRTR5LkK0OVEh\|ryP	NH[xdoZUSU6JRWK=
NY	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mm\aTWM2OD12OT6zPVA5KM7:TR?=	M1XidnNCVkeHUh?=
NCI-H2291	NV3yVHVPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHryR4ZKSzVyPUS5Mlg{ODFizszN	NInSUlNUSU6JRWK=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	Ac-Histone H4 / Ac-Histone H3; PubMed: 21598070 J Neurooncol D54 and U87 glioma cells were treated with lower concentrations (1-3 µM) of vorinostat. The effects on histone acetylation was assessed by immunoblotting. phospho-CDK1; PubMed: 21598070 Changes in level of inhibitory phosphorylation of cdk1 after treatment with vorinostat was determined at 24 and 48 h (using a Tyr-15 residue phospho-specific antibody) along with total cdk1 as loading control. phospho-Cdc25c / Cdc25c; PubMed: 21598070 J Neurooncol Time course of changes in phospho-cdc25c levels after exposure to vorinostat (5 µM). Cyclin B1; PubMed: 21598070 J Neurooncol Cyclin B1 levels were determined in D54 and U87 cells after treatment with various doses of vorinostat at 24 and 48 h. c-Myc / c-Raf / Akt / Cyclin D1 / CDK4; PubMed: 19440035 Cancer Biol Ther Cell lysates from JeKo-1 and Mo2058 cells exposed to vorinostat were immunoblotted for c-Myc, c-Raf, AKT, cyclin D1, CDK4 and acetylated histone H3. The levels of β-actin served as the loading control. p-eIF2α / ATF4 / CHOP ; PubMed: 20072656 Neoplasia Western blot was performed to evaluate activated eIF2α (P-eIF2α), translational up-regulation of ATF4, and CHOP expression in U251 cells after vorinostat exposure. p21; PubMed: 21598070 J Neurooncol To determine the dose response relationship to vorinostat, cells were exposed to various higher concentrations (5–10 µM) of the agent and the levels of p21 determined by immunoblotting.	21598070 19440035 20072656
Immunofluorescence	HDAC1 / CK19; PubMed: 29917299 Cancer Sci Immunocytochemistry to detect the expression of HDAC1 and CK 19 in PDAC cells with/without Vorinostat treatment. HDAC1 and CK19 were stained red and green, respectively. The Hoechst‐stained nuclei appear blue. Scale bar: 100 μm. The CK19 expression in PSN1 and MiaPaCa2 was increased by Vorinostat treatment. Nrf2; PubMed: 20566897 Blood Vorinostat induced translocation of Nrf2 from cytosol to nucleus. U937 cells were treated with 2μM vorinostat for 18 hours and then cytospun. Cells were fixed and labeled for Nrf2 protein (red) and nucleus (blue, 4,6-diamidino-2-phenylindole) as described in “Immunofluorescence and confocal microscopy.” Images were taken by Nikon Eclipse TE2000 confocal microscope with 40×/1.30 numeric aperture oil objective lens. Ctrl indicates control cells without treatment; and Vor, vorinostat. α-SMA; PubMed: 26330748 Mol Vis Representative immunofluorescence images and the quantification graph showing the effect of vorinostat (2.5 µM), TGIF1, and TGIF2 siRNA knockdown on αSMA. Control human corneal fibroblast cultures (-TGFβ) showed no αSMA staining. Cultures treated with TGFβ1 (5 ng/ml) showed a robust αSMA staining. Vorinostat treatment markedly attenuated TGFβ-evoked αSMA staining. The knockdown of TGIF1 (+TGFβ+vorinostat+TGIF1siRNA) and TGIF2 alone (+TGFβ+vorinostat+TGIF2siRNA) or in combination (+TGFβ +vorinostat +TGIF1 +2siRNA) markedly blocked the effect of vorinostat on αSMA. Scale bar=100 μm. Ac-STAT3 / IGF2; PubMed: 27086926 Oncogene Immunofluorescence staining of Ac-STAT3 and IGF2 after vorinostat treatment.	29917299 20566897 26330748 27086926
Growth inhibition assay	Cell apoptosis; PubMed: 19440035 Cancer Biol Ther Cells were treated with indicated concentrations of vorinostat for 48 hours. Following this, the percentage of annexin-V-stained apoptotic cells was determined by flow cytometry. Values represented as bar graphs are the mean of 3 experiments plus or minus the standard error (SE) Cell viability; PubMed: 27086926 Oncogene The effects of vorinostat on the viability of the indicated NSCLC cell lines and their corresponding acquired VoR sublines. Cell viability was determined by the MTT assay (n = 3).	19440035 27086926
ELISA	IGF2; PubMed: 27086926 Oncogene Determination of vorinostat-induced IGF2 production by ELISA (n = 3). The conditioned mediums (CMs) obtained from cells treated with vorinostat (5 μM) for 2 days were used for ELISA. IL-13 / IL-10 / IL-5; PubMed: 18541724 Blood Effect of vorinostat on TH1/TH2 cytokine secretion in HL cell lines. Cells were incubated with medium or vorinostat (5 μM) for 24 hours and supernatants were examined for cytokine levels by ELISA. Each value represents a mean of 3 independent experiments done in triplicate (± SEM). M-CSF; PubMed: 23042302 Carcinogenesis Primary PyMT tumor cells were treated with SAHA (0-1000nM) for varying time points (8–48h), and supernatants were assayed by ELISA for M-CSF secretion. P < 0.05 and P < 0.001 versus control treatment. MMP-9; PubMed: 23042302 Carcinogenesis Primary PyMT tumor cells were treated with SAHA (0-1000nM) for varying time points (8–48h), and supernatants were assayed by ELISA for MMP-9 secretion. P < 0.05 and **P < 0.001 versus control treatment.	27086926 18541724 23042302

In vivo

Administration of Vorinostat (~100 mg/kg/day) significantly inhibits the growth of CWR22 human prostate xenografts in nude mice with tumor reductions of 78%, 97% and 97%, at doses of 25 mg/kg/day, 50 mg/kg/day and 100 mg/kg/day, respectively, compared with control. Vorinostat induces the accumulation of acetylated core histones and prostate-specific antigen mRNA expression in CWR22 cells, resulting in higher levels of serum prostate-specific antigen than predicted from tumor volume alone. ^[2] Oral administration of Vorinostat (0.67g/L) crosses the blood-brain barrier, increases histone acetylation in the brain, and dramatically improves the motor impairment in the R6/2 mice model of Huntington's disease. ^[5]

Protocol

Kinase Assay: ^[1]	+ Expand Immunoprecipitation-HDAC assays: The lysate of Jurkat cells is incubated for 1 hour on ice and cleared by centrifugation at 12,000 g for 10 minutes at 4 °C. Supernatants are precleared with 30 μL of 50% protein G-Sepharose slurry for 1 hour at 4 °C. Beads are pelleted by centrifugation and supernatants are incubated for 1 hour at 4 °C with 10 μg of IgG fraction from anti-HDAC1 or HDAC3 polyclonal antisera (preincubated 2 hours at room temperature with either the homologous or heterologous immunizing peptide). Both antisera are raised in rabbits against the carboxylterminal peptide of HDAC1 and HDAC3 by using synthetic peptides coupled to keyhole limpet hemocyanin. 30 μL of 50% protein G-Sepharose slurry is added for 1 hour at 4 °C. Immune complexes are pelleted by centrifugation and washed three times with 1 mL of lysis buffer. Beads are resuspended in 200 μL of HDAC buffer (20 mM Tris-HCl, pH 8.0/150 mM NaCl/10% glycerol), and the HDAC assay is performed with an ³H-acetylated peptide corresponding to amino acids 1-24 of histone H4. Released [³H]acetic acid is quantified by scintillation counting. For inhibitions studies, the immunoprecipitated complexes are preincubated with the different concentrations of Vorinostat for 30 minutes at 4 °C.
Cell Research: ^[2]	+ Expand Cell lines: LNCaP, PC-3, and TSU-Pr1 Concentrations: Dissolved in DMSO, final concentrations ~7.5 μM Incubation Time: 1, 2, 3 and 4 days Method: Cells are exposed to various concentrations of Vorinostat for 1, 2, 3 and 4 days. Cell viability is assessed by trypan blue dye exclusion. (Only for Reference)
Animal Research: ^[2]	+ Expand Animal Models: Male BALB/c nude (nu/nu) mice implanted with CWR22 tumor cells Formulation: Dissolved in DMSO Dosages: ~100 mg/kg/day Administration: Injection i.p. (Only for Reference)

References

+ Expand

Solubility (25°C)

In vitro	DMSO	52 mg/mL (196.74 mM)
	Ethanol	3 mg/mL (11.35 mM)
	Water	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 2% DMSO+30% PEG 300+5% Tween 80+ddH2O For best results, use promptly after mixing.	5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Vorinostat (SAHA, MK0683) SDF

Molecular Weight	264.3
Formula	C₁₄H₂₀N₂O₃
CAS No.	149647-78-9
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	SAHA, MK0683, suberoylanilide hydroxamic acid

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-03-27)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03022565	Recruiting	Uveal Melanoma	University of Miami\|University of Miami Sylvester Comprehensive Cancer Center	July 2019	Early Phase 1
NCT03022565	Recruiting	Uveal Melanoma	University of Miami\|University of Miami Sylvester Comprehensive Cancer Center	July 2019	Early Phase 1
NCT03843528	Not yet recruiting	Acute Myeloid Leukemia\|Myelodysplastic Syndromes\|Mixed Phenotype Acute Leukemia\|Juvenile Myelomonocytic Leukemia	Johns Hopkins All Children''s Hospital	May 1 2019	Phase 1
NCT03843528	Not yet recruiting	Acute Myeloid Leukemia\|Myelodysplastic Syndromes\|Mixed Phenotype Acute Leukemia\|Juvenile Myelomonocytic Leukemia	Johns Hopkins All Children''s Hospital	May 1 2019	Phase 1
NCT03742245	Not yet recruiting	Breast Cancer Metastatic\|Breast Cancer	Jenny C. Chang MD\|AstraZeneca\|The Methodist Hospital System	April 1 2019	Phase 1
NCT03742245	Not yet recruiting	Breast Cancer Metastatic\|Breast Cancer	Jenny C. Chang MD\|AstraZeneca\|The Methodist Hospital System	April 1 2019	Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
What’s the recommendation about reconstitution of the compound for in vivo animal study?
Answer:
We recommend the following vehicle for S1047: 2% DMSO, 40% PEG 300, 5% Propylene glycol, 1% Tween 80 at 5 mg/mL.

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Selective HDAC Inhibitor

RGFP966 : HDAC3-selective, IC50=80 nM.
Selective HDAC Inhibitor

Rocilinostat (ACY-1215) : HDAC5-selective, IC50=5 nM.
Most Potent HDAC Inhibitor

Quisinostat (JNJ-26481585) : HDAC1, IC50=0.11 nM; HDAC2, IC50=0.33 nM.
FDA-approved HDAC Inhibitor

Vorinostat (SAHA, MK0683) : Approved by FDA against cutaneous T cell lymphoma.
Newest HDAC Inhibitor

RG2833 (RGFP109) ^New : Brain-penetrant HDAC inhibitor with IC50 of 60 nM and 50 nM for HDAC1 and HDAC3, respectively.

Related HDAC Products5

LMK-235 ^New

LMK-235 is a selective inhibitor of HDAC4 and HDAC5 with IC50 of 11.9 nM and 4.2 nM, respectively.
CAY10603 ^New

CAY10603 is a potent and selective HDAC6 inhibitor with IC50 of 2 pM, >200-fold selectivity over other HDACs.
Domatinostat (4SC-202) ^New

4SC-202 is a selective class I HDAC inhibitor with IC50 of 1.20 μM, 1.12 μM, and 0.57 μM for HDAC1, HDAC2, and HDAC3, respectively. Also displays inhibitory activity against Lysine specific demethylase 1 (LSD1). Phase 1.
Panobinostat (LBH589)

Panobinostat (LBH589) is a novel broad-spectrum HDAC inhibitor with IC50 of 5 nM in a cell-free assay. Phase 3.
Entinostat (MS-275)

Entinostat (MS-275) strongly inhibits HDAC1 and HDAC3 with IC50 of 0.51 μM and 1.7 μM in cell-free assays, compared with HDACs 4, 6, 8, and 10. Phase 3.
Trichostatin A (TSA)

Trichostatin A (TSA) is an HDAC inhibitor with IC50 of ~1.8 nM in cell-free assays.
Romidepsin (FK228, Depsipeptide)

Romidepsin (FK228, depsipeptide) is a potent HDAC1 and HDAC2 inhibitor with IC50 of 36 nM and 47 nM in cell-free assays, respectively.

Features:More effective than other classical HDAC inhibitors such as TSA, TPX, and butyrate.
RGFP966

RGFP966 is an HDAC3 inhibitor with IC50 of 0.08 μM in cell-free assay, exhibits > 200-fold selectivity over other HDAC.
Tubastatin A

Tubastatin A is a potent and selective HDAC6 inhibitor with IC50 of 15 nM in a cell-free assay. It is selective against all the other isozymes (1000-fold) except HDAC8 (57-fold).
Mocetinostat (MGCD0103)

Mocetinostat (MGCD0103) is a potent HDAC inhibitor with most potency for HDAC1 with IC50 of 0.15 μM in a cell-free assay, 2- to 10- fold selectivity against HDAC2, 3, and 11, and no activity to HDAC4, 5, 6, 7, and 8. Phase 2.

Choose Your Country or Region

By Signaling Pathways

By product type

Vorinostat (SAHA, MK0683)

Cited by 112 Publications

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Vorinostat (SAHA, MK0683) SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-03-27)

Tech Support

Frequently Asked Questions

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Related HDAC Products5

Choose Your Country or Region

By Signaling Pathways

By product type

Vorinostat (SAHA, MK0683)

Cited by 112 Publications

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Vorinostat (SAHA, MK0683) SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-03-27)

Tech Support

Frequently Asked Questions

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Related HDAC Products5

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)